{
    "url": "https://www.sec.gov/Archives/edgar/data/1445815/000149315224015358/form10-q.htm",
    "report_type": "10-Q",
    "context": [
        {
            "id": 0,
            "context": "Item 1. Unaudited Condensed Consolidated Financial Statements: BIOXYTRAN, Inc., March 31, 2024\nBIOXYTRAN, INC.\nCONDENSED CONSOLIDATED BALANCE SHEETS\nAS OF MARCH 31, 2024 AND DECEMBER 31, 2023\n(UNAUDITED)\n\n| March 31, 2024 | December 31, 2023 |\n| ASSETS |\n| Current assets |\n| Cash | $ | 10,024 | $ | 26,086 |\n| Total current assets | 10,024 | 26,086 |\n| Intangibles, net | 115,516 | 111,552 |\n| Total assets | $ | 125,540 | $ | 137,638 |\n| LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT |\n| Current liabilities |\n| Accounts payable and accrued expenses | $ | 97,591 | $ | 296,312 |\n| Accounts payable affiliate | 1,457 | 2,000 |\n| Un-issued shares liability | 14,246 | 510,284 |\n| Un-issued shares liability affiliate | 30,000 | 515,904 |\n| Un-issued shares liability | 30,000 | 515,904 |\n| Short term loan | 38,000 | \u2014 |\n| Short term loan affiliate | 73,107 | 25,000 |\n| Short term loan | 73,107 | 25,000 |\n| Convertible notes payable, net of premium and discount | 861,500 | 1,900,000 |\n| Total current liabilities | 1,115,901 | 3,249,500 |\n| Total liabilities | 1,115,901 | 3,249,500 |\n| Commitments and contingencies | \u2014 | \u2014 |\n| Stockholders\u2019 deficit |\n| Preferred stock, $ 0.001 par value; 50,000,000 shares authorized, nil issued and outstanding | \u2014 | \u2014 |\n| Common stock, $ 0.001 par value; 300,000,000 shares authorized; 173,032,028 and 145,642,333 issued and outstanding as at March 31, 2024 and December 31, 2023, respectively | 173,032 | 145,642 |\n| Additional paid-in capital | 15,828,748 | 12,920,984 |\n| Non-controlling interest | ( 694,210 | ) | ( 680,886 | ) |\n| Accumulated deficit | ( 16,297,931 | ) | ( 15,497,602 | ) |\n| Total stockholders\u2019 deficit | ( 990,361 | ) | ( 3,111,862 | ) |\n| Total liabilities and stockholders\u2019 deficit | $ | 125,540 | $ | 137,638 |",
            "type": "table"
        },
        {
            "id": 1,
            "context": "See the accompanying notes to these unaudited condensed consolidated financial statements\n\nBIOXYTRAN, INC.\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\nIN THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023\n(UNAUDITED)\n\n| 3-Months Ended |\n| March 31, 2024 | March 31, 2023 |\n| Operating expenses |\n| Research and development | $ | 27,000 | $ | 139,004 |\n| General and administrative | 446,546 | 587,638 |\n| General and administrative affiliate | 10,000 | 10,000 |\n| Compensation expense | 168,410 | 850 |\n| Compensation expense affiliate | 131,835 | 12,750 |\n| Total operating expenses | 783,791 | 750,242 |\n| Loss from operations | ( 783,791 | ) | ( 750,242 | ) |\n| Other expenses: |\n| Interest expense | ( 26,734 | ) | ( 67,221 | ) |\n| Interest expense affiliate | ( 1,097 | ) | \u2014 |\n| Amortization of IP | ( 2,031 | ) | ( 514 | ) |\n| Total other expenses | ( 29,862 | ) | ( 67,735 | ) |\n| Net loss before provision for income taxes | ( 813,653 | ) | ( 817,977 | ) |\n| Provision for income taxes | \u2014 | \u2014 |\n| Net loss | ( 813,653 | ) | ( 817,977 | ) |\n| Net loss attributable to the non-controlling interest | 13,324 | 32,894 |\n| NET LOSS ATTRIBUTABLE TO BIOXYTRAN | $ | ( 800,329 | ) | $ | ( 785,083 | ) |\n| Loss per common share, basic and diluted | $ | ( 0.00 | ) | $ | ( 0.01 | ) |\n| Weighted average number of common shares outstanding, basic and diluted | 162,808,026 | 123,495,291 |",
            "type": "table"
        },
        {
            "id": 2,
            "context": "See the accompanying notes to these unaudited condensed consolidated financial statements\n\nBIOXYTRAN, INC.\nCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 DEFICIT\nIN THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023\n(UNAUDITED)\n\n| Common Stock | Preferred Stock | Additional Paid in Capital | Accumulated | Non- controlling | Total |\n| Shares | Amount | Shares | Amount | Common | Preferred | Deficit | Interest | Deficit |\n| January 1, 2023 | 123,252,235 | $ | 123,252 | \u2014 | \u2014 | $ | 8,392,430 | $ | \u2014 | $ | ( 11,217,600 | ) | $ | ( 590,628 | ) | $ | ( 3,292,546 | ) |\n| Stock transactions | 250,000 | 250 | - | 79,750 | 80,000 |\n| Stock subscription | - | - | ( 30,000 | ) | ( 30,000 |\n| Net loss attributable to the non-controlling interest | ( 32,894 | ) | ( 32,894 | ) |\n| Net loss | - | - | - | - | - | ( 785,083 | ) | - | ( 785,083 | ) |\n| March 31, 2023 | 123,502,235 | $ | 123,502 | \u2014 | \u2014 | $ | 8,442,180 | $ | \u2014 | $ | ( 12,002,683 | ) | $ | ( 623,522 | ) | $ | ( 4,060,523 | ) |\n| January 1, 2024 | 145,642,333 | $ | 145,642 | \u2014 | \u2014 | $ | 12,920,984 | $ | \u2014 | $ | ( 15,497,602 | ) | $ | ( 680,886 | ) | ( 3,111,862 | ) |\n| Balance | 145,642,333 | $ | 145,642 | \u2014 | \u2014 | $ | 12,920,984 | $ | \u2014 | $ | ( 15,497,602 | ) | $ | ( 680,886 | ) | ( 3,111,862 | ) |\n| Stock transactions | ( 1,000,000 | ) | ( 1,000 | ) | - | 1,000 | \u2014 |\n| Stock subscription | 333,333 | 333 | ( 333 | ) | \u2014 |\n| Shares issued affiliate - 2021 Plan | 1,190,460 | 1,191 | 130,645 | 131,836 |\n| Shares issued - 2021 Plan | 1,643,231 | 1,643 | 166,805 | 168,448 |\n| Shares issued for the conversion of accounts payable affiliate | 3,599,289 | 3,599 | 482,305 | 485,904 |\n| Shares issued for the conversion of accounts payable | 7,409,512 | 7,410 | 877,994 | 885,404 |\n| Shares issued for the conversion of notes payable and accrued interest | 9,857,092 | 9,857 | 1,253,705 | 1,263,562 |\n| Shares issued for the conversion of warrants | 4,356,778 | 4,357 | ( 4,357 | ) | \u2014 |\n| Net loss attributable to the non-controlling interest | ( 13,324 | ) | ( 13,324 | ) |\n| Net loss | - | - | - | - | - | ( 800,329 | ) | - | ( 800,329 | ) |\n| March 31, 2024 | 173,032,028 | $ | 173,032 | \u2014 | \u2014 | $ | 15,828,748 | $ | \u2014 | $ | ( 16,297,931 | ) | $ | ( 694,210 | ) | $ | ( 990,361 | ) |\n| Balance | 173,032,028 | $ | 173,032 | \u2014 | \u2014 | $ | 15,828,748 | $ | \u2014 | $ | ( 16,297,931 | ) | $ | ( 694,210 | ) | $ | ( 990,361 | ) |",
            "type": "table"
        },
        {
            "id": 3,
            "context": "See the accompanying notes to these unaudited condensed consolidated financial statements\n\nBIOXYTRAN, INC.\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\nIN THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023\n(UNAUDITED)\n\n| 3-Months Ended |\n| March 31, 2024 | March 31, 2023 |\n| CASH FLOWS FROM OPERATING ACTIVITIES |\n| Net loss | $ | ( 813,653 | ) | $ | ( 817,977 | ) |\n| Adjustments to reconcile net loss to net cash used in operating activities |\n| Amortization of IP | 2,031 | 514 |\n| Stock-based compensation expense | 168,410 | 850 |\n| Stock-based compensation expense affiliate | 131,835 | 12750 |\n| Interest paid for conversion of note | 163,562 | \u2014 |\n| Changes in operating assets and liabilities |\n| Accounts payable and accrued expenses | 273,151 | 351,474 |\n| Accounts payable and accrued expenses affiliate | ( 903 | ) | 265,500 |\n| Net cash used in operating activities | ( 75,567 | ) | ( 186,889 | ) |\n| CASH FLOWS FROM INVESTING ACTIVITIES |\n| Investment in intangibles | ( 5,995 | ) | ( 4,711 | ) |\n| Net cash used in investing activities | ( 5,995 | ) | ( 4,711 | ) |\n| CASH FLOWS FROM FINANCING ACTIVITIES |\n| Proceeds from subsidiary stock transactions | \u2014 | 50,000 |\n| Proceeds from stock subscriptions | 4,000 | \u2014 |\n| Proceeds from issuance of convertible notes payable | 61,500 | \u2014 |\n| Net cash provided by financing activities | 65,500 | 50,000 |\n| Net increase (decrease) in cash | ( 16,062 | ) | ( 141,600 | ) |\n| Cash, beginning of period | 26,086 | 295,401 |\n| Cash, end of period | $ | 10,024 | $ | 153,801 |\n| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |\n| Interest paid | $ | \u2014 | $ | 52,425 |\n| Income taxes paid | $ | \u2014 | $ | \u2014 |\n| NON-CASH INVESTING & FINANCING ACTIVITIES |\n| Common shares issued for the conversion of principal and accrued interest | $ | 1,263,562 | $ | \u2014 |\n| Common shares issued for the conversion of accounts payable | 885,404 | \u2014 |\n| Common shares issued for the conversion of accounts payable affiliate | $ | 485,904 | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 4,
            "context": "See the accompanying notes to these unaudited condensed consolidated financial statements\n\nBIOXYTRAN, INC.\nNOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\nIN THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023\n(UNAUDITED)\nNOTE 1 \u2013 BACKGROUND AND ORGANIZATION\nBusiness Operations Bioxytran, Inc. (the \u201cCompany\u201d) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner.",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "Our Subsidiary, Pharmalectin, Inc. (the \u201cSubsidiary\u201d) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to viral diseases.\nOur Foreign Subsidiary, Pharmalectin (BVI), Inc. (the \u201cForeign Subsidiary\u201d) is the owner and custodian of the Company\u2019s Copyrights, Trademarks and Patents.\nOur subsidiary, Pharmalectin India Pvt Ltd. (\u201cPharmalectin India\u201d) is managing the Company\u2019s local clinical research and trials, and holds the local rights to commercialization.\nOrganization Bioxytran, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized shares of Common Stock with a par value of $ 0.0001 , and 5,000,000 shares of Preferred Stock with a par value of $ 0.0001 . On September 21, 2018, the Company underwent a reorganization in the form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized Common shares with a par value of $ 0.001 , and 50,000,000 Preferred shares with a par value of $ 0.001 . As at March 31, 2024 there are 173,032,028 shares of Common Stock issued and outstanding; 94,083,520 shares ( 54.4 %) are beneficially held by insiders, or their affiliates; a non-affiliated shareholder beneficially owns 14,027,606 shares ( 8.1 %)",
            "type": "paragraph"
        },
        {
            "id": 6,
            "context": "Pharmalectin was organized on October 5, 2017, as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized shares of Common Stock with a par value of $ 0.0001 , and 5,000,000 shares of Preferred Stock, none outstanding, with a par value of $ 0.0001 . The Subsidiary was founded under the name of Bioxytran \u201cBioxytran (DE)\u201d. On April 29, 2020, the name was changed to Pharmalectin, Inc. As at March 31, 2024, there are 29,410,000 shares of Common Stock issued and outstanding; 15,000,000 ( 51 %) shares are held by Bioxytran and 14,410,000 shares ( 49 %) are held by an affiliate where the beneficial ownership includes Mike Sheikh, Ola Soderquist and David Platt.",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "Pharmalectin BVI was organized on March 17, 2021, as a British Virgin Islands (BVI) Business Corporation with a BVI corporate taxing structure with 50,000 authorized and outstanding shares with a par value of $ 1.00 . The Company holds 100% of the shares in the Subsidiary.",
            "type": "paragraph"
        },
        {
            "id": 8,
            "context": "Pharmalectin India Pvt Ltd. (\u201cPharmalectin India\u201d) was organized on August 30, 2022, as an Indian Business Corporation with its principal place of business in Hyderabad, Telangana, India, with 50,000 authorized shares with a par value of $ 0.12 (\u20b9 10 ). There are currently 41,020 outstanding shares whereof 41,000 ( 99.95 %) are held by the Company.",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the \u201cSEC\u201d), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements.",
            "type": "paragraph"
        },
        {
            "id": 10,
            "context": "While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of the management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (\u201cUS GAAP\u201d). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company\u2019s December 31, 2022, audited financial statements and notes.",
            "type": "paragraph"
        },
        {
            "id": 11,
            "context": "Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation, its majority owned subsidiary, Pharmalectin, Inc. of Delaware, as well as its wholly owned subsidiaries, Pharmalectin (BVI), Inc. of British Virgin Islands and Pharmalectin India Pvt Ltd. (collectively, the \u201cCompany\u201d). All intercompany accounts have been eliminated upon consolidation.",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES\nA summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.\nCash\nFor purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity date of three months or less to be cash equivalents.\nUse of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company\u2019s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (\u201cASC 260-10\u201d). Net loss per common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the \u201ctreasury stock\u201d and/or \u201cif converted\u201d methods as applicable.",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "At March 31, 2024, we would, based on the market price of $ 0.1058 /share, be obligated to issue approximately 9,253,173 shares of Common Stock upon conversion of the currently outstanding convertible notes (the \u201c2021 Notes\u201d), 2,422,144 shares upon exercise of the warrants, and 290,000 shares upon exercise of outstanding options, or a total of 11,965,317 shares of Common Stock. For the Notes, the shares total is based on $ 948,071 of currently outstanding principal, and unpaid interest.",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "The notes issued in 2021 (the \u201c2021 Note\u201d), have an interest rate of 10% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) if the market price at the date of conversion is below $0.13, the conversion price will be reduced with 120% of the difference between conversion and market price. The notes issued in 2024 (the \u201c2024 Note\u201d), have an interest rate of 8% and are convertible at a fixed price of $0.13",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "The 14,410,000 ( 49 %) shares of Common Stock in the Subsidiary, owned by an affiliate, come with an option to convert into a 16.8 % ownership in the Company on a fully diluted basis, currently 42,892,010 shares of Common Stock.",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "Stock Based Compensation The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash.",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "Accounting for subsidiary stock transactions The Company accounts for subsidiary stock transactions in accordance with Opinions of the Accounting Principles Board 09 (APBO No. 9). In paragraph 28, this pronouncement excluded all adjustments from transactions in a company\u2019s own stock \u201c\u2026from the determination of net income or the results of operations under all circumstances.\u201d",
            "type": "paragraph"
        },
        {
            "id": 19,
            "context": "Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (\u201cASC 730-10\u201d). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. In the three months ended March 31, 2024, the Company incurred $ 27,000 in research and development expenses, while during the three months ended March 31, 2023, the Company incurred $ 139,004 .",
            "type": "paragraph"
        },
        {
            "id": 20,
            "context": "Intangibles \u2013 Goodwill and Other Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company\u2019s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent.",
            "type": "paragraph"
        },
        {
            "id": 21,
            "context": "Accrued Expenses As part of the process of preparing our condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under, or over, -estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.",
            "type": "paragraph"
        },
        {
            "id": 22,
            "context": "Warrants The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.",
            "type": "paragraph"
        },
        {
            "id": 23,
            "context": "Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (\u201cASC 825-10\u201d) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.",
            "type": "paragraph"
        },
        {
            "id": 24,
            "context": "The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (\u201cASC 820-10\u201d) and Accounting Standards Codification subtopic 825-10, Financial Instruments (\u201cASC 825-10\u201d), which permits entities to choose to measure many financial instruments and certain other items at fair value.",
            "type": "paragraph"
        },
        {
            "id": 25,
            "context": "Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\u201cASU\u201d) 2020-06, Debt \u2014 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging \u2014 Contracts in Entity\u2019s Own Equity (Subtopic 815-40) (\u201cASU 2020-06\u201d) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity\u2019s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity\u2019s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company\u2019s financial statements.",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company\u2019s unaudited condensed interim financial statements.\nNOTE 3 \u2013 GOING CONCERN AND MANAGEMENT\u2019S LIQUIDITY PLANS As at March 31, 2024, the Company had cash of $ 10,024 and a negative working capital of $ 1,105,877 . The Company has not yet generated any revenues, and has incurred cumulative net losses of $ 16,297,931 . These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "During the three months ended March 31, 2024, the Company raised a net of $ 4,000 in cash proceeds from equity and $ 61,500 in cash proceeds from the issuance of convertible notes. During the same period in 2022, the Company raised a net of $ 50,000 in cash proceeds from subsidiary stock transactions. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of June, 2024 and is pursuing alternative opportunities to funding.",
            "type": "paragraph"
        },
        {
            "id": 28,
            "context": "The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.",
            "type": "paragraph"
        },
        {
            "id": 29,
            "context": "The Company\u2019s management does not know the full extent or foresee the impact COVID-19 has had on our business or our operations or its ability to carry out our plans. We will continue to monitor and follow this situation closely. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "NOTE 4 - AFFILIATE TRANSACTIONS The Company holds License Agreements (the \u201cLicense(s)\u201d or \u201cAgreement(s)\u201d) for a medical device (license obtained in 2019) and a compound (license obtained in 2021), with two affiliated companies where the beneficial ownership includes Mike Sheikh, Ola Soderquist and David Platt. The products were developed prior to the establishment of Bioxytran. The maintenance fees for each license amount to $ 5,000 per year. During the three months ended March 31, 2024, there was $ 10,000 in transactions with affiliates. During the same period in 2023, there was $ 10,000 in transactions with affiliates for license maintenance.",
            "type": "paragraph"
        },
        {
            "id": 31,
            "context": "The Company had at March 31, 2024 loan agreements calling for an 8 % interest with two of its affiliates, one loan is for $ 35,070 with an accrued interest of $ 1,064 , while the other is for $ 38,037 with an accrued interest of $ 33 . As at December 31, 2023 there was a loan for $ 25,000 with an accrued interest of $ 542 .",
            "type": "paragraph"
        },
        {
            "id": 32,
            "context": "NOTE 5 - INTANGIBLES Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment charges were recorded in the 3 months ended March 31, 2024, and the year ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "Amortization of capitalized patent costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at the award date, which varies depending on the pendency period of the application, generally approximating twenty years.",
            "type": "paragraph"
        },
        {
            "id": 34,
            "context": "SCHEDULE OF INTANGIBLES\n\n| Estimated Remaining Life (years) | March 31, 2024 | December 31, 2023 |\n| Capitalized patent costs | 18 | $ | 129,475 | $ | 123,480 |\n| Accumulated amortization | ( 13,959 | ) | ( 11,929 | ) |\n| Intangible assets, net | $ | 115,516 | $ | 111,552 |",
            "type": "table"
        },
        {
            "id": 35,
            "context": "NOTE 6 \u2013 ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On March 31, 2024, there was $ 1,097 in interest due and $ 73,107 in loans from affiliates, and $ 30,000 in un-issued shares liability affiliate. On December 31, 2023, there was $ 2,000 in accounts payable and $ 25,000 in loans from affiliates, and $ 515,904 in un-issued shares liability affiliate.",
            "type": "paragraph"
        },
        {
            "id": 36,
            "context": "The following table represents the major components of accounts payables and accrued expenses and other current liabilities at March 31, 2024, and at December 31, 2023:\nSCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES\n\n| March 31, 2024 | December 31, 2023 |\n| Accounts payable affiliate (1) | $ | \u2014 | $ | 2,000 |\n| Professional fees | 10,363 | 70,895 |\n| Interest affiliate (2) | 1,457 | \u2014 |\n| Interest | 86,571 | 223,759 |\n| Other | 657 | 1,658 |\n| Un-issued share liability, affiliate (3) | 30,000 | 515,904 |\n| Un-issued share liability, consultant | 14,246 | 510,284 |\n| Short term loan from Affiliate (2) | 73,107 | 25,000 |\n| Short term Loan | 38,000 | \u2014 |\n| Convertible note payable | 861,500 | 1,900,000 |\n| Total current liabilities | $ | 1,115,901 | $ | 3,249,500 |",
            "type": "table"
        },
        {
            "id": 37,
            "context": "| (1) | On December 31, 2023, there was $ 2,000 due to the CFO for advanced expenses. |\n| (2) | On March 31, 2024, the Company has a loan of $ 73,107 from affiliates, the interest is 8 % and is currently $ 1,457 . On December 31, 2023, the loan was $ 25,000 . |\n| (3) | On March 31, 2024, there are 241,938 shares of Common Stock awarded but not issued to three Board Members in the first quarter of 2024. The total fair market value at the time of the award was $ 30,000 . On December 31, 2023, there were 211,269 shares awarded but not issued to three Board Members. The total fair market value at the time of the award was $ 30,000 . There were also 3,599,289 shares not issued, but converted, from salaries and expenses by the management for a fair market value of $ 485,904 . |",
            "type": "table"
        },
        {
            "id": 38,
            "context": "NOTE 7 \u2013 CONVERTIBLE NOTES PAYABLE\nPrivate Placement, 2021 Notes currently outstanding Around May 3, 2021, we entered into four (4) Securities Purchase Agreements (the \u201c2021 SPA\u2019s\u201d), under which we agreed to sell convertible promissory notes (the \u201c2021 Notes\u201d), in an aggregate principal amount of $ 2,165,000 with 6 % interest.",
            "type": "paragraph"
        },
        {
            "id": 39,
            "context": "At any time after the issue date of the Notes, the Holders of the Notes, (the \u201c2021 Holders\u201d), have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the 2021 Notes into shares of our Common Stock at the Conversion Price. The \u201cConversion Price\u201d will be the lesser of (i) $.13 per share or (ii) 85% of the closing price of Any Qualified Financing, which consists of any fundraising whereby the Company receives gross proceeds of not less than $500,000 .",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "If the 2021 Notes are converted prior to us paying off such note, it would lead to substantial dilution to our shareholders as a result of the conversion discounted applicable to the 2021 Notes. There can be no assurance that there will be any funds available to pay of the 2021 Notes. If we fail to obtain such additional financing on a timely basis, the 2021 Holders may convert the 2021 Notes and sell the underlying shares, which may result in significant dilution to shareholders due to the conversion discount, as well as a significant decrease in our stock price.",
            "type": "paragraph"
        },
        {
            "id": 41,
            "context": "On May 5, 2023, three (3) of the Notes were renegotiated; the interest was set to 10 %, a prepayment at 120 % was included and the Notes extended until April 30, 2024 . The conversion price was adjusted to the lower of (i) a fixed price of $0.13, or (ii) if the market price at the date of conversion is below $0.13, the conversion price will be reduced with 120% of the difference between conversion and market price.",
            "type": "paragraph"
        },
        {
            "id": 42,
            "context": "At March 31, 2024 and December 31, 2023, the outstanding convertible notes were as follows:\nSCHEDULE OF OUTSTANDING CONVERTIBLE NOTES\n\n| Name | Principal due | Accrued interest | Total amount due |\n| December 31, 2023 |\n| Private Placement, 2021 Note | (1 | ) | $ | 900,000 | $ | 63,814 | $ | 963,814 |\n| 2021 Note issued in exchange for prior Notes | (2 | ) | 1,000,000 | 159,945 | 1,159,945 |\n| $ | 1,900,000 | $ | 223,759 | $ | 2,123,759 |",
            "type": "table"
        },
        {
            "id": 43,
            "context": "| March 31, 2024 |\n| Private Placement, 2021 Note | (3 | ) | $ | 800,000 | $ | 85,978 | $ | 885,978 |",
            "type": "table"
        },
        {
            "id": 44,
            "context": "| (1) | Net cash received from these notes were $ 1,045,150 , after a Debt Discount of $ 119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC). |\n| (2) | All earlier issued Notes were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $ 1,000,000 was issued to a third party. |\n| (3) | In the first quarter of 2024 a total of $ 1,263,562 (whereof $ 163,562 in interest) was converted into 9,857,092 shares of Common Stock. The remaining \u201c2021 Note\u201d has an interest rate of 10% and is convertible at the lower of (i) a fixed price of $0.13, or (ii) if the market price at the date of conversion is below $0.13, the conversion price will be reduced with 120% of the difference between conversion and market price. |",
            "type": "table"
        },
        {
            "id": 45,
            "context": "Private Placement, 2024 On March 15, 2024, we entered into a Security Purchase Agreements (the \u201c2024 SPA\u2019s\u201d), with an accredited investor, under which we agreed to sell a Note, in a principal amount of $ 61,500 with 8 % interest (the \u201c2024 Note\u201d) to the holders of the 2024 Note (the \u201c2024 Holder\u201d).",
            "type": "paragraph"
        },
        {
            "id": 46,
            "context": "At any time after the issue date of the 2024 Note, the 2024 Holder has the option to convert any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Note into shares of our Common Stock at the Conversion Price. The \u201cConversion Price\u201d is set to $ 0.13 per share.",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "The Common Stock underlying the 2024 Note, when issued, bear a restrictive legend and are currently eligible for resale under Rule 144.\nSCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL\n\n| Name | Principal due | Accrued interest | Total amount due |\n| March 31, 2024 |\n| Private Placement, 2024 Note | $ | 61,500 | $ | 593 | 62,093 |",
            "type": "table"
        },
        {
            "id": 48,
            "context": "NOTE 8 \u2013 STOCKHOLDERS\u2019 EQUITY\nThe Company is authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock.\n\nPreferred Stock\nAs at March 31, 2024, no Preferred shares have been designated nor issued.\nCommon Stock\nAs at January 1, 2023, there were 123,252,235 shares of Common Stock issued and outstanding.\nIssuances in the period January 1 and March 31, 2023 On January 4, 2023 the Company issued 93,750 shares of Common Stock against $ 30,000 included in Stockholders Equity as Stock Subscription at December 31, 2022, or 0.32 /share.",
            "type": "paragraph"
        },
        {
            "id": 49,
            "context": "On February 10, 2023 the Company issued 156,250 shares of Common Stock against $ 50,000 , or 0.32 /share.\nIssuances in the period January 1 and March 31, 2024\nOn January 17, 2024, the Company issued 333,333 shares of Common Stock in a private placement against $ 45,000 , or 0.135 /share.\nOn January 18, 2024, the Company issued 3,703,704 shares of Common Stock in exchange for invoices of $ 500,000 , or 0.135 /share. On January 18, 2024, the Company issued 3,599,289 shares of Common Stock to offset an affiliate against invoices paid on behalf of the Company and accrued salaries to our Officers, for a total value of $ 485,904 , or 0.135 /share.",
            "type": "paragraph"
        },
        {
            "id": 50,
            "context": "On January 19, 2024, the Company returned 1,000,000 shares of Common Stock into treasury. The shares outstanding at year end were included in the value of Common Stock and reversed in Additional Paid in Capital (\u201cAPIC\u201d) at par, $ 1,000 .",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "On March 20, 2024, the Company issued 906,618 shares of Common Stock against a principal of $ 100,000 from the remaining 2021 Note, or 0.11 /share. On January 22, 2024, the Company issued 4,356,778 shares of Common Stock in a cash-less exercise in exchange for 5,066,264 shares in Pharmalectin at a fixed conversion rate of 1.18864 /share. The Subsidiary cancelled 1,358,466 option shares with provisions for dilutive issuance and cash-less exercise.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "On January 22, 2024, the Company issued 8,950,474 shares of Common Stock in conversion of a note of $ 1,000,000 and $ 163,562 in interest, or 0.13 /share.",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "On March 27, 2024, the Company issued 3,705,808 in exchange for invoices in the amount of $ 385,404 , or 0.104 /share.\n2021 Stock Plan issuances in the period January 1 and March 31, 2024 In the first three months of 2024, the Company issued 1,190,460 shares of Common Stock to its Board members and Management for their contribution throughout the year 2023. The shares had a fair value of $ 131,836 , or an average of 0.111 /share.",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "In the first three months of 2024, the Company issued 1,643,231 shares of Common Stock to twelve consultants for their contribution throughout the year 2023. The shares had a fair value of $ 168,448 , or an average of 0.103 /share.",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "As at March 31, 2024, the Company has 173,032,028 shares of Common Stock issued and outstanding.\nCommon Stock Warrants\nIn the 3 months ended March 31, 2024 and 2023 the Company did not issue any Warrants.\nThe following table summarizes the Company\u2019s Common Stock warrant activity in the 3 months ended March 31, 2024 and 2023:\nSCHEDULE OF WARRANT ACTIVITY\n\n| Number of Warrants* | Weighted Average Exercise Price | Weighted- Average Remaining Expected Term |\n| Outstanding as at January 1, 2023 | 542,030 | $ | 0.42 | 4.1 |\n| Granted | \u2014 | \u2014 | \u2014 |\n| Exercised | \u2014 | \u2014 | \u2014 |\n| Forfeited/Canceled | \u2014 | \u2014 | \u2014 |\n| Outstanding as at March 31, 2023 | 542,030 | $ | 1.14 | 3.8 |\n| Outstanding as at January 1, 2024 | 1,342,030 | $ | 0.29 | 3.8 |\n| Granted | \u2014 | \u2014 | \u2014 |\n| Exercised | \u2014 | \u2014 | \u2014 |\n| Forfeited/Canceled | \u2014 | \u2014 | \u2014 |\n| Outstanding as at March 31, 2024 | 1,342,030 | $ | 0.29 | 3.5 |",
            "type": "table"
        },
        {
            "id": 56,
            "context": "The following table summarizes information about stock warrants that are vested or expected to vest at March 31, 2024, with a market price of $ 0.1058 at March 31, 2024:\nSCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS\n\n| Warrants Outstanding | Exercisable Warrants |\n| Number of Warrants | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | Number of Warrants | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value |\n| 1,342,030 | $ | 0.29 | 3.5 | $ | \u2014 | 1,342,030 | $ | 0.29 | 3.5 | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 57,
            "context": "The weighted-average remaining contractual life for warrants exercisable at December 31, 2023, is 3.5 years. The aggregate intrinsic value for fully vested, exercisable warrants was $ 0 at March 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 58,
            "context": "NOTE 9 \u2013 STOCK OPTION PLAN AND STOCK-BASED COMPENSATION On January 15, 2021, the Company adopted a stock option plan entitled \u201cThe 2021 Stock Plan\u201d (2021 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15 % of the then fully diluted number of shares of the Company\u2019s Common Stock, automatically adjusted on January 1 each year. On January 1, 2024, the 2021 Employee, Director and Consultant Stock Plan (the \u201c2021 Plan\u201d) was reset in accordance with its stipulations. After the reset there were 30,028,314 shares of Common Stock awards available for grant.",
            "type": "paragraph"
        },
        {
            "id": 59,
            "context": "As at January 1, 2024, there were 335,000 outstanding stock options valued at historic fair market value of $ 155,505 and a cumulative 5,288,687 shares issued valued at a fair historic market value of $ 99,910 at the time of award. As at March 31, 2023, there existed \u201cThe 2010 Stock Plan\u201d and under this plan there were 524,000 outstanding stock options with a fair historic market value of $ 173,362 and a cumulative 4,290,709 shares issued with a negative (historically awarded \u201cexpensive\u201d stock was returned to treasury in 2021) fair historic market value of $ 97,272 at the time of award.",
            "type": "paragraph"
        },
        {
            "id": 60,
            "context": "Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance.",
            "type": "paragraph"
        },
        {
            "id": 61,
            "context": "SCHEDULE OF FAIR MARKET VALUE\n\n| Number of Shares | Fair Value per Share | Weighted Average Market Value per Share |\n| Shares Issued as of January 1, 2023 | 4,290,709 | $ | 0.001 \u2013 0.550 | $ | ( 0.020 | ) |\n| Shares Issued | \u2014 | \u2014 | \u2014 |\n| Shares Issued as of March 31, 2023 | 4,290,709 | 0.001 \u2013 0.550 | ( 0.020 | ) |\n| Shares Issued as of January 1, 2024 | 5,288,687 | 0.001 \u2013 0.550 | 0.020 |\n| Shares Issued | 2,833,691 | 0.106 \u2013 0.142 | 0.108 |\n| Shares Issued as of March 31, 2024 | 8,122,378 | $ | 0.001 \u2013 0.550 | $ | 0.049 |",
            "type": "table"
        },
        {
            "id": 62,
            "context": "In the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense of $ 300,245 and $ 13,600 , respectively, in connection with share-based payment awards. There were no awards from the 2021 Plan in the three months ended March 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "Issuances in the period January 1 and March 31, 2024 On March 27, 2024 the Company issued 211,269 shares of Common Stock to three Board members for their contribution during the fourth quarter of 2023. The shares had a fair value of $ 30,000 and were included in Stockholders Equity as Stock Subscription at December 31, 2023, or $ 0.142 /share.",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "On March 27, 2024 the Company issued 72,423 shares of Common Stock to three Consultants for their contribution during the fourth quarter of 2023. The shares had a fair value of $ 10,284 and were included in Stockholders Equity as Stock Subscription at December 31, 2023, or $ 0.142 /share.",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "On March 27, 2024 the Company issued 979,191 shares of Common Stock, as an equity bonus for the year 2023, to its Board and Management. The shares had a fair value of $ 100,855 , or $ 0.104 /share.",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "On March 27, 2024 the Company issued 1,520,808 shares of Common Stock, as an equity bonus to thirteen Consultants that had contributed to the Company\u2019s R&D during 2023. The shares had a fair value of $ 158,643 , or $ 0.104 /share.",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "On March 27, 2024 the Company mistakenly issued 50,000 shares of Common Stock, $ 50 was accounted in Common Stock against APIC.\nStock options granted and vested 2021 Plan: There were no stock options granted the three months ended March 31, 2024, while, 45,000 were forfeited. There were no stock options granted the three months ended March 31, 2024, while, 48,000 were forfeited.",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "The following table summarizes the Company\u2019s stock option activity in the three months ended March 31, 2024, and 2023:\nSCHEDULE OF STOCK OPTIONS ACTIVITY\n\n| Number of Options | Exercise Price per Share | Weighted Average Exercise Price per Share |\n| Outstanding as of January 1, 2023 | 524,000 | $ | 0.001 \u2013 0.95 | $ | 0.71 |\n| Granted | \u2014 | \u2014 | \u2014 |\n| Exercised | \u2014 | \u2014 | \u2014 |\n| Options forfeited/cancelled | ( 48,000 | ) | 0.15 \u2013 0.32 | 0.16 |\n| Outstanding as of March 31, 2023 | 476,000 | $ | 0.001 - 0.95 | $ | 0.47 |\n| Outstanding as of January 1, 2024 | 335,000 | $ | 0.001 - 0.95 | $ | 0.62 |\n| Granted | \u2014 | \u2014 | \u2014 |\n| Exercised | \u2014 | \u2014 | \u2014 |\n| Options forfeited/cancelled | ( 45,000 | ) | 0.34 | 0.34 |\n| Outstanding as of March 31, 2024 | 290,000 | $ | 0.001 - 0.95 | $ | 0.68 |",
            "type": "table"
        },
        {
            "id": 69,
            "context": "The following table summarizes information about stock options that are vested or expected to vest at March 31, 2024:\nSCHEDULE OF STOCK OPTION VESTED\n\n| Options Outstanding | Exercisable Options |\n| Exercise Price | Number of Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | Number of Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value |\n| $ | 0.001 | 45,000 | $ | 0.001 | 0.33 | $ | 4,635 | 45,000 | $ | 0.001 | 0.33 | $ | 4,635 |\n| 0.19 | 45,000 | 0.19 | 0.08 | \u2014 | 45,000 | 0.19 | 0.08 | \u2014 |\n| 0.95 | 200,000 | 0.95 | 0.45 | \u2014 | 200,000 | 0.95 | 0.45 | \u2014 |\n| $ | 0.001 - 1.21 | 290,000 | $ | 0.68 | 0.38 | $ | 4,635 | 290,000 | $ | 0.68 | 0.38 | $ | 4,635 |",
            "type": "table"
        },
        {
            "id": 70,
            "context": "There were no granted options granted, nor any options issued in the period ended March 31, 2024 and 2023:\nThe weighted-average remaining estimated life for options exercisable at March 31, 2024 is 0.38 years. The aggregate intrinsic value for fully vested, exercisable options was $ 4,635 at March 31, 2024 and at December 31, 2023 was $ 6,750 . The actual tax benefit realized from stock option exercises in the three months ended at March 31, 2024 and 2023 was $ 0 as no options were exercised.",
            "type": "paragraph"
        },
        {
            "id": 71,
            "context": "As at March 31, 2024 the Company has 27,242,623 options or stock awards available for grant under the 2021 Plan.\n\nNOTE 10 \u2013 NON-CONTROLLING INTEREST\nSCHEDULE OF NON CONTROLLING INTEREST\n\n| March 31, 2024 | December 31, 2023 |\n| Net loss Subsidiary | ( 27,191 | ) | ( 333,630 | ) |\n| Net loss attributable to the non-controlling interest | 13,324 | 90,258 |\n| Net loss affecting Bioxytran | ( 13,867 | ) | ( 243,372 | ) |\n| Accumulated losses | ( 3,955,108 | ) | ( 3,927,917 | ) |\n| Accumulated losses attributable to the non-controlling interest | 855,160 | 841,836 |\n| Accumulated losses affecting Bioxytran | ( 3,099,948 | ) | ( 3,086,081 | ) |\n| Net equity non-controlling interest | ( 694,210 | ) | ( 680,886 | ) |",
            "type": "table"
        },
        {
            "id": 72,
            "context": "As at March 31, 2024, there are 29,410,000 issued and outstanding shares in Pharmalectin; 15,000,000 ( 51 %) shares of Common Stock are held by Bioxytran and 14,410,000 shares ( 49 %) are held by an affiliate where the beneficial ownership includes Mike Sheikh, Ola Soderquist and David Platt. As per the exchange terms in the Joint Venture Agreement dated November 15, 2020, the affiliate has the option to convert 15,000,000 shares in the Subsidiary into a 17.5 %, or a pro-rated quantity thereof, ownership in Company. If the option is exercised, it would result in significant dilution to shareholders which could lead to a significant decrease in our stock price, based on how the market perceive the value of fully control the Subsidiary.",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "NOTE 11 \u2013 COMMITMENTS AND CONTINGENCIES\nEmployment contracts\nOur Executive Officers have entered into employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The most substantial provisions include;\n\n| \u25cf | Compensation of three (3) times the employee\u2019s annual salary upon the Termination Date and any target bonus earned, or if termination occurs within 12 months of a change in control, then the terminated employee shall receive two (2) times the employee\u2019s annual salary and any target bonus earned. |\n| \u25cf | Continued coverage under any health, medical, dental or vision program or policy, in which they were eligible to participate at the time of employment termination, for 12 months. |\n| \u25cf | Provide outplacement services through one or more outside firms of the employee\u2019s choosing up to an aggregate of $ 50,000 . |",
            "type": "table"
        },
        {
            "id": 74,
            "context": "There are no other arrangements or plans in which we provide pension, retirement or similar benefits for any of Executive Officers or Directors.\nLitigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.",
            "type": "paragraph"
        },
        {
            "id": 75,
            "context": "NOTE 12 \u2013 SUBSEQUENT EVENTS\nThe Company has evaluated events from March 31, 2024 through the date the financial statements were issued. The events requiring disclosure for this period are as follows;\nRemuneration Adjustment by Management Team\nThe management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.\n\nCommon stock\nStock Subscription On May 15, 2024, the Company issued 173,077 shares of Common Stock for a cash investment of $ 18,000 , or $ 0.104 /share. $ 4,000 of these funds were included as unissued shares in the financial statements at March 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 76,
            "context": "Conversion of Note\nOn May 15, 2024, the Company issued 479,192 shares of Common Stock in conversion of a note of $ 61,500 and $ 795 in interest, or $ 0.13 /share.\nShares Awarded under the 2021 Stock Plan On April 4, 2024, the Company issued 1,000,000 shares of Common Stock to a consultant as payment for a 12-month investor relations agreement. The shares fair value was $ 104,000 , or $ 0.104 /share.",
            "type": "paragraph"
        },
        {
            "id": 77,
            "context": "On April 5, 2024 the Company corrected an issuance of 50,000 made on March 27, 2023. $ 50 was transferred from Common Stock to APIC. On May 19, 2024, the Company issued 241,938 shares of Common Stock to affiliates for their service in the Board of Directors during the first quarter of 2024. The fair value of these shares was $ 30,000 , or $ 0.124 /share. The issuance was included as unissued shares related party in the financial statements at March 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "On May 19, 2024, the Company issued 86,246 shares of Common Stock to non-affiliates for their services during the first quarter of 2024. The fair value of these shares was $ 10,246 , or $ 0.124 /share. The issuance was included as unissued shares related party in the financial statements at March 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 79,
            "context": "Management sees no further subsequent events requiring disclosure.\n\n The following discussion and analysis is based on, and should be read in conjunction with, the audited financial statements and the notes thereto for the two years ended December 31, 2023, included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 31, 2024. This discussion contains forward-looking statements. These statements are often identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201ccould,\u201d \u201cestimate,\u201d or \u201ccontinue,\u201d and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.",
            "type": "paragraph"
        },
        {
            "id": 80,
            "context": "Overview We do not currently have sufficient capital resources to fund operations. To stay in business and to continue the development of our products, we will need to raise additional capital through public or private sales of our securities, debt financing or short-term bank loans, or a combination of the foregoing. We believe that if we can raise $3,700,000, we will have sufficient working capital to develop our business over the next approximately fifteen (15) months. At funding raised that is significantly less than $3,700,000, we can likely continue to develop our business over the same 15-month period, but funding at that level will delay the development of our technology and business.",
            "type": "paragraph"
        },
        {
            "id": 81,
            "context": "Bioxytran, Inc. is headquartered in Needham, Massachusetts. The Company\u2019s initial product pipeline is focused on developing and commercializing therapeutic molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis drug specifically designed to treat a person immediately after that person suffers an ischemic stroke. The drug is designed to be injected intravenously to travel to the lungs to pick up oxygen molecules to carry to the brain. Like a red blood cell, the drug will cross the blood brain barrier, which is a protective semi-permeable membrane allowing some material to cross but preventing others from crossing. BXT-25 will be designed to diffuse oxygen into the brain tissues. We expect the BXT-25 molecule to be 5,000 times smaller than a red blood cell.",
            "type": "paragraph"
        },
        {
            "id": 82,
            "context": "Our Subsidiary is focusing on the development, manufacturing and commercialization of therapeutic drugs designed to address viral diseases in humans. The Company has developed a novel method designed to reduce the viral load and modulate the immune system using a Galectin Antagonist. The lead drug candidate is a glyco-virology platform technology named ProLectin, a complex galectin antagonist that binds to, and blocks the activity of galectin-3, a type of galectin. During viral infections galectins are upregulated and downregulated based on the type of virus. To our knowledge, Pharmalectin, Inc. is the only company planning to develop, what we believe is a viable, end-to-end solution for upper respiratory viruses. We are also the only company, to our knowledge, attempting to use a Galectin Antagonist to combat upper respiratory viruses, eg SARS-CoV-2, Influenza N1H1 and Respiratory Syncytial Virus (RSV).",
            "type": "paragraph"
        },
        {
            "id": 83,
            "context": "On December 2, 2022, India\u2019s Central Drugs Standard Control Organisation (CDSCO) issued an IND with permission to conduct: \u201cA Phase 1b/2a Randomized, Blinded, placebo-controlled Study in Participants with Mild to Moderate COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Orally Administered ProLectin-M\u201d. The trial is planned to start on, or around, October 1, 2023.",
            "type": "paragraph"
        },
        {
            "id": 84,
            "context": "On August 21, 2023, the Company\u2019s IND #153742 under the title \u201cPROTECT: ProLectin-M, a nucleocapsid TErminal GaleCTin antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded Clinical Trial to Evaluate the Efficacy and Safety in Non-Hospitalized Adult Participants with COVID-19\u201d was approved by the FDA, the trial is expected to start in the first quarter of 2024, provided we obtain adequate funding.",
            "type": "paragraph"
        },
        {
            "id": 85,
            "context": "On January 27, 2023, an additional IND with the CDSCO was issued for ProLectin-I for an \u201cIV treatment of SARS-CoV-2 in hospitalized patients with moderate Covid-19 infections and for Long Covid\u201d, and for ProLectin-F for \u201ctreatment of lung-fibrosis as a result of use of ventilator\u201d.",
            "type": "paragraph"
        },
        {
            "id": 86,
            "context": "On April 19, 2023, the Company announced that its Acelluar Oxygen Carrier (\u201cAOC\u201d) BXT-25 has been successfully tested in animals. The initial results are very encouraging because they show the non-toxicity of the experimental drug, along with the corresponding full recovery in Swiss Albino mice, in an experiment carried out in a joint venture with NDPD Pharma, Inc. As a next step, the Company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.",
            "type": "paragraph"
        },
        {
            "id": 87,
            "context": "The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. The Company currently has convertible loans outstanding at a total face value of $861,500. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $16,297,931 as at March 31, 2024. The accumulated deficit as at December 31, 2023, was $15,497,602.",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "The future of the Company is dependent upon its ability to obtain financing to develop its new business opportunities and support the cost of the drug development including clinical trials and regulatory submission to the FDA. Management plans to seek additional capital through private placements and public offerings of its Common Stock. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital or the establishment of strategic relationships with established pharmaceutical companies, the Company may be required to cease operations. These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.",
            "type": "paragraph"
        },
        {
            "id": 89,
            "context": "RESULTS OF OPERATIONS IN THE THREE MONTHS ENDED MARCH 31, 2024 and 2023 We are a clinical stage company. Historically, Bioxytran was engaged in formation, fund raising and identifying and consulting with the scientific community regarding the development, formulation and testing of its products as of the fourth quarter of 2021 the Company has engaged in research and development activities through its Subsidiary, Pharmalectin, Inc., developing the ProLectin-Rx.",
            "type": "paragraph"
        },
        {
            "id": 90,
            "context": "Research and Development\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Research and development |\n| Process development | $ | \u2014 | $ | \u2014 |\n| Product development | \u2014 | \u2014 |\n| Regulatory | \u2014 | 47,004 |\n| Clinical trials | \u2014 | 74,000 |\n| Project management | 27,000 | 18,000 |\n| Total research and development | $ | 27,000 | $ | 139,004 |",
            "type": "table"
        },
        {
            "id": 91,
            "context": "General and Administrative expenses\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Payroll and related expenses | $ | 377,122 | $ | 359,142 |\n| Costs for legal, accounting and other professional services | 6,676 | 43,113 |\n| Promotional expenses | 22,000 | 165,251 |\n| Miscellaneous expenses | 50,749 | 30,132 |\n| Total general and administrative expenses | $ | 456,546 | $ | 597,638 |",
            "type": "table"
        },
        {
            "id": 92,
            "context": "| Payroll and related expenses in the three months ended March 31, 2024 were $377,122 compared to $359,142 in the three months ended March 31, 2024. The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first. |\n| The Costs for legal, accounting and other professional services in the three months ended March 31, 2024 decreased due to reduced activity for lack of funding. |\n| Promotional expenses in the three months ended March 31, 2024 were $22,000, as compared to $165,251In the three months ended March 31, 2023. Promotional activities were paid upfront without possibility of claw back. |\n| Miscellaneous G&A expenses during the three months ended March 31, 2024 and 2023 was $50,749 and $30,132, respectively. The difference is due to training expenses |",
            "type": "table"
        },
        {
            "id": 93,
            "context": "Stock-based Compensation\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Compensation expense to BoD and Management | $ | 131,835 | $ | 12,750 |\n| Compensation expense to consultants | 168,410 | 850 |\n| Total compensation expense | $ | 300,245 | $ | 13,600 |",
            "type": "table"
        },
        {
            "id": 94,
            "context": "Other expenses\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Interest expense | 26,734 | 67,221 |\n| Interest expense affiliate | 1,097 | \u2014 |\n| Amortization of IP | 2,031 | 514 |\n| Total other income (expenses) | $ | 29,862 | $ | 67,735 |",
            "type": "table"
        },
        {
            "id": 95,
            "context": "Non-Controlling Interest\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Net loss attributable to the non-controlling interest | $ | 13,324 | $ | 32,894 |\n| Net equity non-controlling interest | (694,210 | ) | (623,552 | ) |",
            "type": "table"
        },
        {
            "id": 96,
            "context": "| # of shares | # of options | March 31, 2024 | December 31, 2023 |\n| Minority owners cash investment | 14,410,000 | $ | 160,950 | $ | 160,950 |\n| Bioxytran interest in subsidiary | 15,000,000 | 1,500 | 1,500 |\n| Total outstanding | 29,410,000 | \u2014 | $ | 162,450 | $ | 162,450 |",
            "type": "table"
        },
        {
            "id": 97,
            "context": "Net Loss\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Net loss attributable to Bioxytran | $ | (800,329 | ) | $ | (785,083 | ) |\n| Loss per common share, basic and diluted | $ | (0.00 | ) | $ | (0.01 | ) |\n| Weighted average number of common shares outstanding, basic | 162,808,026 | 123,495,291 |",
            "type": "table"
        },
        {
            "id": 98,
            "context": "CASH-FLOWS\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Net cash used in operating activities | $ | (75,567 | ) | $ | (186,889 | ) |\n| Net cash used in investing activities | (5,995 | ) | (4,711 | ) |\n| Net cash provided by financing activities | 65,500 | 50,000 |\n| Net increase (decrease) in cash | $ | (16,062 | ) | $ | (141,600 | ) |\n| Cash, beginning of period | 26,086 | 295,401 |\n| Cash, end of period | 10,024 | 153,801 |",
            "type": "table"
        },
        {
            "id": 99,
            "context": "| Net cash used in operating activities was $75,567 and $186,890 in the three months ended March 31, 2024 and 2023, respectively. The decrease was due to a reduction of the research and development activities due to lack of funding. |\n| In the Three months ended March 31, 2024 the Company is in the process of filing a patent, and $5,995 was spent in legal fees. in the Three months ended March 31, 2023 the amount was $4,711. |\n| Cash flows from financing activities were $65,500 and $50,000 in the three months ended March 31, 2024 and 2023, respectively. |\n| The available cash was $10,024 and $153,801 in the end of the Three months ended March 31, 2024 and 2023, respectively. |",
            "type": "table"
        },
        {
            "id": 100,
            "context": "LIQUIDITY AND CAPITAL RESOURCES\nCurrent Assets\n\n| March 31, 2024 | December 31, 2023 |\n| Cash | $ | 10,024 | $ | 26,086 |\n| Total current assets | $ | 10,024 | $ | 26,086 |",
            "type": "table"
        },
        {
            "id": 101,
            "context": "Current Liabilities\n\n| March 31, 2024 | December 31, 2023 |\n| Accounts payable and accrued expenses | $ | 97,591 | $ | 296,312 |\n| Accounts payable affiliate | 1,457 | 2,000 |\n| Un-issued shares liability | 14,246 | 510,284 |\n| Un-issued shares liability affiliate | 30,000 | 515,904 |\n| Short term loan | 38,000 |\n| Short term loan affiliate | 73,107 | 25,000 |\n| Convertible notes payable, net of discount | 861,500 | 1,900,000 |\n| Total current liabilities | 1,115,901 | 3,249,500 |",
            "type": "table"
        },
        {
            "id": 102,
            "context": "Net Working Capital and Accumulated Deficit\n\n| March 31, 2024 | December 31, 2023 |\n| Net working capital | $ | (1,105,877 | ) | $ | (3,223,414 | ) |\n| Accumulated deficit | $ | (16,297,931 | ) | $ | (15,497,602 | ) |",
            "type": "table"
        },
        {
            "id": 103,
            "context": "Cash Proceeds from Financing Activities\n\n| Three months ended |\n| March 31, 2024 | March 31, 2023 |\n| Proceeds from stock transactions | $ | 4,000 | $ | 50,000 |\n| Proceeds from issuance of convertible notes payable | 61,500 | \u2014 |\n| Net cash provided by financing activities | $ | 65,500 | $ | 50,000 |",
            "type": "table"
        },
        {
            "id": 104,
            "context": "Upcoming Financing Activities\nThe Company intends to issue a Private Placement Offering under Regulation D in the order of three (3) million dollars in first half of 2024. There can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.",
            "type": "paragraph"
        },
        {
            "id": 105,
            "context": "Commitments We have no current commitment from our officers and Directors or any of our shareholders, to supplement our operations or provide us with financing in the future. If we are unable to raise additional capital from conventional sources and/or additional sales of stock in the future, we may be forced to curtail or cease our operations. Even if we are able to continue our operations, the failure to obtain financing could have a substantial adverse effect on our business and financial results. in the future, we may be required to seek additional capital by selling debt or equity securities, selling assets, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency. The sale of additional equity or debt securities, if accomplished, may result in dilution to our then shareholders. We provide no assurance that financing will be available in amounts or on terms acceptable to us, or at all.",
            "type": "paragraph"
        },
        {
            "id": 106,
            "context": "Off-Balance Sheet Arrangements\nWe do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.\nCRITICAL ACCOUNTING POLICIES In presenting our financial statements in conformity with generally accepted accounting principles, we are required to make estimates and assumptions that affect the amounts reported therein. Several of the estimates and assumptions we are required to make relate to matters that are inherently uncertain as they pertain to future events. However, events that are outside of our control cannot be predicted and, as such, they cannot be contemplated in evaluating such estimates and assumptions. If there is a significant unfavorable change to current conditions, it could result in a material adverse impact to our results of operations, financial position and liquidity. We believe that the estimates and assumptions we used when preparing our financial statements were the most appropriate at that time. Presented below are those accounting policies that we believe require subjective and complex judgments that could potentially affect reported results. However, the majority of our businesses operate in environments where we pay a fee for a service performed, and therefore the results of the majority of our recurring operations are recorded in our financial statements using accounting policies that are not particularly subjective, nor complex.",
            "type": "paragraph"
        },
        {
            "id": 107,
            "context": "Stock Based Compensation The Company has share-based compensation plans under which non-employees, consultants and suppliers may be granted restricted stock, as well as options to purchase shares of Company Common Stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award over the requisite service period.",
            "type": "paragraph"
        },
        {
            "id": 108,
            "context": "The Company applies ASC 718 for options, common stock and other equity-based grants to its employees and directors. ASC 718 requires measurement of all employee equity-based payment awards using a fair-value method and recording of such expense in the consolidated financial statements over the requisite service period. The fair value concepts have not changed significantly in ASC 718; however, in adopting this standard, companies must choose among alternative valuation models and amortization assumptions. After assessing alternative valuation models and amortization assumptions, the Company will continue using both the Black-Scholes valuation model and straight-line amortization of compensation expense over the requisite service period for each separately vesting portion of the grant.",
            "type": "paragraph"
        },
        {
            "id": 109,
            "context": "Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\u201cASU\u201d) 2020-06, Debt \u2014 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging \u2014 Contracts in Entity\u2019s Own Equity (Subtopic 815-40) (\u201cASU 2020-06\u201d) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity\u2019s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity\u2019s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of AASU 2020-06 did not have an impact on the Company\u2019s financial statements.",
            "type": "paragraph"
        },
        {
            "id": 110,
            "context": "Item 3 is not applicable to us because we are a smaller reporting company.\n\nEvaluation of Disclosure Controls and Procedures Our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) reviewed the effectiveness of our disclosure controls and procedures as at the end of the period covered by this report and concluded that as at March 31, 2024, (i) the Company\u2019s disclosure controls and procedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the \u201cCommission\u201d), and (ii) the Company\u2019s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company\u2019s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.",
            "type": "paragraph"
        },
        {
            "id": 111,
            "context": "Based on this evaluation, our principal executive officer and principal financial officer concluded as at the evaluation date that our disclosure controls and procedures were not effective due primarily to a material weakness in the segregation of duties in the Company\u2019s internal controls.\nManagement\u2019s Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2024. in making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (\u201cCOSO\u201d) in Internal Control-Integrated Framework (2013). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.",
            "type": "paragraph"
        },
        {
            "id": 112,
            "context": "As disclosed in our previous filings, there are material weaknesses in the Company\u2019s internal control over financial reporting due to the fact that the Company does not have an adequate process established to ensure appropriate levels of review of accounting and financial reporting matters, which resulted in our closing process not identifying all required adjustments and disclosures in a timely fashion. The Company\u2019s CEO/CFO has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. The small size of the Company\u2019s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation.",
            "type": "paragraph"
        },
        {
            "id": 113,
            "context": "Although the Company has hired a consultant to assist with SEC reporting and accounting matters, we expect that the Company will need to hire accounting personnel with the requisite knowledge to improve the levels of review of accounting and financial reporting matters. The Company may experience delays in doing so and any such additional employees would require time and training to learn the Company\u2019s business and operating processes and procedures. For the near-term future, until such personnel are in place, this will continue to constitute a material weakness in the Company\u2019s internal control over financial reporting that could result in material misstatements in the Company\u2019s financial statements not being prevented or detected.",
            "type": "paragraph"
        },
        {
            "id": 114,
            "context": "Because of the above material weakness, management has concluded that we did not maintain effective internal control over financial reporting as of March 31, 2024, based on the criteria established in \u201cInternal Control-Integrated Framework\u201d issued by the COSO.",
            "type": "paragraph"
        },
        {
            "id": 115,
            "context": "No Attestation Report by Independent Registered Accountant\nThe effectiveness of our internal control over financial reporting as of March 31, 2024 has not been audited by our independent registered public accounting firm by virtue of our exemption from such requirement as a smaller reporting company.\nChanges in Internal Controls Over Financial Reporting There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the 3 months ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.",
            "type": "paragraph"
        },
        {
            "id": 116,
            "context": "Inherent Limitations on Effectiveness of Controls The Company\u2019s management does not expect that its disclosure controls or its internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system\u2019s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.",
            "type": "paragraph"
        },
        {
            "id": 117,
            "context": "PART II - OTHER INFORMATION\n\nThe Company may become involved in certain legal proceedings and claims which arise in the normal course of business.\n\nThe Company is a smaller reporting company and is not required to provide this information.\n\nThere were no sales of equity securities sold during the period covered by this Report that were not previously included in a Current Report on Form 8-K. The Company claims an exemption from the registration requirements of the Securities Act of 1933 (the \u201cSecurities Act\u201d) for the private placement of these securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.",
            "type": "paragraph"
        },
        {
            "id": 118,
            "context": "There are currently no defaults upon Senior Securities.\n\nNot Applicable.\n\nEffective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased). Dr. Radka Milanova holds a PhD in Organic Chemistry from Simon Fraser University, Canada. Dr. Milanova\u2019s professional experience includes executive positions with various biotechnology companies. She has championed and captained five Investigational New Drug Applications (\u201cIND\u201d) and two successful New Drug Applications (\u201cNDA\u201d), led Research and Development programs, invented eight granted patents and seventeen publications, obtained millions in grants, associated with licensing deals and business development agreements that achieved winning commercialization results, maximizing global market share and generating millions in revenues. Our Board of Directors believes that Dr. Milanova\u2019s expertise and experience in practicing pharmaceutical development, her perspective, depth and background in business development and out-licensing, and her leadership experience in the field of biotechnology provide her with the qualifications and skills to serve on our Board of Directors.",
            "type": "paragraph"
        },
        {
            "id": 119,
            "context": "| Exhibit No. | Title of Document |\n| 10.83 | * | Option Agreement for conversion/exchange between Pharmalectin, Inc. and Bioxytran, Inc. shares of Common Stock, dated November 20, 2021. |\n| 31.1 | * | Certification of Principal Executive and Financial Officers pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. |\n| 32.1 | ** | Certification pursuant to Section 906 of Sarbanes Oxley Act of 2002 (Chief Executive and Financial Officer). |\n| 100 | The following financial statements from the Quarterly Report on Form 10-Q of BIOXYTRAN, Inc. for the quarter ended March 31, 2024 formatted in XBRL: (i) Condensed Balance Sheets (unaudited), (ii) Condensed Statements of Operations (unaudited), (iii) Condensed Statements of Cash Flows (unaudited), and (iv) Notes to Condensed Financial Statements (unaudited), tagged as blocks of text. |\n| 101.INS | Inline XBRL Instance Document |\n| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |\n| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |\n| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |\n| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |\n| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |\n| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |",
            "type": "table"
        },
        {
            "id": 120,
            "context": "SIGNATURES\nIn accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.\n\n| BIOXYTRAN, INC. |\n| Date: April 19, 2024 | By: | /s/ David Platt |\n| David Platt |\n| Chief Executive Officer |\n| /s/ Ola Soderquist |\n| Ola Soderquist |\n| Chief Financial Officer |",
            "type": "table"
        },
        {
            "id": 121,
            "context": "",
            "type": "paragraph"
        }
    ],
    "html_tables": [
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_308_111_zTCiLKWbO0c2\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_498_20240331_zS551OwyX6v6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31, </b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2024</b></span></p></td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_493_20231231_zN41WvxlZUkl\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>December 31, </b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2023</b></span></p></td><td>\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AssetsAbstract_iB_z8ILFA6wC86f\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">ASSETS</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_znmVBUh354Nc\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--Cash_i02I_maCzyjp_z5DgTwnbj7m5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%\">Cash</td><td style=\"width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\"> 10,024 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\"> 26,086 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--AssetsCurrent_i02TI_mtCzyjp_maCz506_z0Un8ZtPpyG6\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Total current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,024 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 26,086 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maCz506_zf9FwumuViPl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Intangibles, net</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 115,516 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 111,552 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--Assets_i01TI_mtCz506_z1s2FjmYvte1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Total assets</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 125,540 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 137,638 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zAQID5bUVgeb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzNtb_zqjxzgLQAOJd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Accounts payable and accrued expenses</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 97,591 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 296,312 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzNtb_zCKgvzkoRela\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Accounts payable affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,457 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzNtb_zyMuWo5MjgB\" style=\"vertical-align: bottom; background-color: White\"> <td>Un-issued shares liability</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,246 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 510,284 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzNtb_zKzour8o1NBe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Un-issued shares liability affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 515,904 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzNtb_zI9SigFAV3Vi\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Un-issued shares liability </td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 515,904 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzNtb_zcOUrCEozcxa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Short term loan</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 38,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0080\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzNtb_zuqV15jXIDb3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Short term loan affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 73,107 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzNtb_zAv248cNFK2k\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Short term loan </td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 73,107 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLCzNtb_zqi2zV7SbB79\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Convertible notes payable, net of premium and discount</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 861,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,900,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_maCzYnC_mtLCzNtb_zXs6LuZvecYk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,115,901 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,249,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--Liabilities_i01TI_mtCzYnC_maCzZje_zo2xKedxQfHg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,115,901 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,249,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maCzZje_zGjWPVUalEP2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Commitments and contingencies</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0097\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0098\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--StockholdersEquityAbstract_i01B\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Stockholders\u2019 deficit</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--PreferredStockValue_i02I_maCzFoh_zymhKKruqS06\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\"><p style=\"margin-top: 0; margin-bottom: 0\">Preferred stock, $<span id=\"xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331_zW3Bpn58zRse\" title=\"Preferred stock, par value\"><span id=\"xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zhhOYUgqGJxe\" title=\"Preferred stock, par value\">  0.001  </span></span> par value; <span id=\"xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331_zjdyZJkGKm35\" title=\"Preferred stock, shares authorized\"><span id=\"xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zhJcTY94IpMc\" title=\"Preferred stock, shares authorized\">  50,000,000  </span></span> shares authorized, <span id=\"xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20240331_zzacPsb18Tbe\" title=\"Preferred stock, shares issued::XDX::-\"><span id=\"xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20240331_z42UsCfVmkca\" title=\"Preferred stock, shares outstanding::XDX::-\"><span id=\"xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20231231_z8Q5ubxGCN57\" title=\"Preferred stock, shares issued::XDX::-\"><span id=\"xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20231231_zsn6YKorZ0L3\" title=\"Preferred stock, shares outstanding::XDX::-\"><span style=\"-sec-ix-hidden: xdx2ixbrl0114\"><span style=\"-sec-ix-hidden: xdx2ixbrl0116\"><span style=\"-sec-ix-hidden: xdx2ixbrl0118\"><span style=\"-sec-ix-hidden: xdx2ixbrl0120\">nil</span></span></span></span></span></span></span></span> issued and outstanding</p></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0103\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0104\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--CommonStockValue_i02I_pp0p0_maCzFoh_zjsE38ajJsy6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\"><p style=\"margin-top: 0; margin-bottom: 0\">Common stock, $<span id=\"xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zEqeCuFPml5b\" title=\"Common stock, par value\"><span id=\"xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zAhX2GAQoTT5\" title=\"Common stock, par value\">  0.001  </span></span> par value; <span id=\"xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zU8qImvmDnEf\" title=\"Common stock, shares authorized\"><span id=\"xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zzRHLEZFjBRl\" title=\"Common stock, shares authorized\">  300,000,000  </span></span> shares authorized; <span id=\"xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20240331_z3jy4CKWcK15\" title=\"Common stock, shares issued\"><span id=\"xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240331_z4K9NHzLiFYi\" title=\"Common stock, shares outstanding\">  173,032,028  </span></span> and <span id=\"xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zBsXg0iwMDGg\" title=\"Common stock, shares issued\"><span id=\"xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zqDUgqQyYqhk\" title=\"Common stock, shares outstanding\">  145,642,333  </span></span> issued and outstanding as at March 31, 2024 and December 31, 2023, respectively</p></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 173,032 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 145,642 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_maCzFoh_zmMgrMHFJvS3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Additional paid-in capital</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 15,828,748 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 12,920,984 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--MinorityInterest_i02I_maCzFoh_zY4zG9Uogxka\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Non-controlling interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 694,210 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 680,886 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzFoh_z1W1TtiyQa5a\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Accumulated deficit</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 16,297,931 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 15,497,602 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_408_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pp0p0_mtCzFoh_maCzZje_zPjIQnzXQtyc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total stockholders\u2019 deficit</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 990,361 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,111,862 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtCzZje_zEHUz3KE3ved\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total liabilities and stockholders\u2019 deficit</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 125,540 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 137,638 </td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30E_113_zynLDc0VicW3\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49D_20240101__20240331_zT6CukpOCfwf\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_492_20230101__20230331_z9sEW8i5kJb8\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">\u00a0</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">3-Months Ended</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31, </b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2024</b></span></p></td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31, </b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2023</b></span></p></td><td>\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zSbqaMh4GhGe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Operating expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz55a_zu2iclOWwFTj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 64%; text-align: left\">Research and development</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 27,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 139,004 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz55a_ziw3yZgRb4s8\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">General and administrative</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 446,546 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 587,638 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_ecustom--GeneralAndAdministrativeAffiliate_i01_maCz55a_zH7GUFP6K4q1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">General and administrative affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--ShareBasedCompensation_i01_maCz55a_zwhhl2eb88Vl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Compensation expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 168,410 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 850 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_ecustom--StockbasedCompensationExpenseAffiliate_i01_maCz55a_z6IksBrIyKJf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Compensation expense affiliate</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 131,835 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 12,750 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--OperatingExpenses_i01T_mtCz55a_msCzVaL_zkuO2fO5Hcqj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total operating expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 783,791 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 750,242 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCzVaL_maCzTGw_zjCoiIwfhISi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Loss from operations</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 783,791 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 750,242 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zYhplcX2RL7i\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Other expenses:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--InterestExpenseDebtExcludingAmortization_i01N_di_msCzi7R_zSRvIDEIN7x3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Interest expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 26,734 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 67,221 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_407_ecustom--InterestExpenseAffiliate_i01N_di_msCzi7R_zLCyqRrXExZ9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Interest expense affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 1,097 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0187\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--AmortizationOfIntangibleAssets_i01N_di_msCzi7R_zUDEYY0iUixh\" style=\"vertical-align: bottom; background-color: White\"> <td>Amortization of IP</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 2,031 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 514 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_maCzTGw_mtCzi7R_zh1TRaH7DQ4c\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total other expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 29,862 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 67,735 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzTGw_maCzmdi_zn5vJhyXd4Bj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net loss before provision for income taxes</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 813,653 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 817,977 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzmdi_zU9CcwOKmv9b\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Provision for income taxes</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0198\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0199\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--ProfitLoss_iT_mtCzmdi_maCztw0_zjCUfDz277R9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Net loss</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 813,653 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 817,977 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_di_msCztw0_zgFRhU24c636\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Net loss attributable to the non-controlling interest</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 13,324 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 32,894 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_iT_mtCztw0_z3FM8Md7ITJd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">NET LOSS ATTRIBUTABLE TO BIOXYTRAN</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 800,329 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 785,083 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Loss per common share, basic and diluted</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_90D_eus-gaap--EarningsPerShareBasic_c20240101__20240331_z2ag0mYpe5U8\" title=\"Loss per Common share, basic\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240101__20240331_za29bctWPthb\" title=\"Loss per Common share, diluted\">(  0.00  </span></span></td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_900_eus-gaap--EarningsPerShareBasic_c20230101__20230331_zojer957iwvd\" title=\"Loss per Common share, basic\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_907_eus-gaap--EarningsPerShareDiluted_c20230101__20230331_zBpdY9gwVKq8\" title=\"Loss per Common share, diluted\">(  0.01  </span></span></td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Weighted average number of common shares outstanding, basic and diluted</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240331_z5UwjEqzJ1zl\" title=\"Weighted average number of Common shares outstanding, basic\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240331_zacuPnTiOJK1\" title=\"Weighted average number of Common shares outstanding, diluted\">  162,808,026  </span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230331_zP2TNhSmrhVf\" title=\"Weighted average number of Common shares outstanding, basic\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA\" id=\"xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230331_zq36KEQSxnnh\" title=\"Weighted average number of Common shares outstanding, diluted\">  123,495,291  </span></span></td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_300_114_z1dTCZ1yMiZf\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zpEygwdI8Yha\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z2f4bBzlhj7h\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockIncludingAdditionalPaidInCapitalMember_zyhKG8APcPu7\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockIncludingAdditionalPaidInCapitalMember_zyuH1DqQRNA3\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zaJRWBQ8dh3k\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zmudBw4GP9Vd\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B0_zL1OgkOSiKO5\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\"><b>\u00a0</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"><b>Common Stock</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"><b>Preferred Stock</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"><b>Additional Paid<br/> in Capital</b></td><td style=\"text-align: center; font-weight: bold\"><b>\u00a0</b></td><td style=\"text-align: center\"><b>\u00a0</b></td> <td colspan=\"2\" style=\"text-align: center\"><b>Accumulated</b></td><td style=\"text-align: center\"><b>\u00a0</b></td><td style=\"text-align: center\"><b>\u00a0</b></td> <td colspan=\"2\" style=\"text-align: center\"><b>Non-<br/> controlling</b></td><td style=\"text-align: center\"><b>\u00a0</b></td><td style=\"text-align: center\"><b>\u00a0</b></td> <td colspan=\"2\" style=\"text-align: center\"><b>Total</b></td><td style=\"text-align: center\"><b>\u00a0</b></td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Common</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Preferred</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"> Deficit</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"> Interest</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"> Deficit</td><td style=\"text-align: center; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_437_c20230101__20230331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zcS9Fm0OW1Ud\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 27%; font-weight: bold\">January 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iS_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRJtvRkXCJu3\" style=\"width: 5%; text-align: right\" title=\"Balance, shares\"> 123,252,235 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\"> 123,252 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--SharesOutstanding_iS_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuc2FZpFi7jf\" style=\"width: 5%; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0236\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 5%; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0227\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\"> 8,392,430 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0229\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\">( 11,217,600 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\">( 590,628 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 5%; text-align: right\">( 3,292,546 </td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr id=\"xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zmtkCSzKxOa1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Stock transactions</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziFa8mC0B2Za\" style=\"text-align: right\" title=\"Stock transactions, shares\"> 250,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 250 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVkcN7EF1EQ4\" style=\"text-align: right\" title=\"Stock transactions, shares\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0248\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 79,750 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 80,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--StockIssuedDuringPeriodValueOther_zAxwZ5n3PwJ\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Stock subscription</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxQ1cjJztny5\" style=\"text-align: right\" title=\"Stock subscription, shares\"><span style=\"display: none; font-family: Times New Roman, Times, Serif\"><span style=\"-sec-ix-hidden: xdx2ixbrl0258\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgwyH4HO5wYb\" style=\"text-align: right\" title=\"Stock subscription, shares\"><span style=\"display: none; font-family: Times New Roman, Times, Serif\"><span style=\"-sec-ix-hidden: xdx2ixbrl0260\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 30,000 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 30,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zzheBuTyjLy1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Net loss attributable to the non-controlling interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 32,894 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 32,894 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--NetIncomeLoss_z31noMw7QKel\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net loss</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0270\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0271\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0272\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0273\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 785,083 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0275\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 785,083 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_437_c20230101__20230331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zt18AmPnmnXl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold\">March 31, 2023</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--SharesOutstanding_iE_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zchiI5pcld9j\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 123,502,235 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 123,502 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--SharesOutstanding_iE_pid_uShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDGk5SNiabCe\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0288\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0279\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 8,442,180 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0281\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 12,002,683 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 623,522 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 4,060,523 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_431_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zFxkv7xHEomc\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold\">January 1, 2024</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFlgfi6JPv8a\" style=\"text-align: right\" title=\"Balance, shares\"> 145,642,333 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 145,642 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4MRWbEcgTUb\" style=\"text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0300\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0291\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 12,920,984 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0293\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 15,497,602 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 680,886 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,111,862 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_437_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zVRLq1qWDug7\" style=\"display: none; vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold\">Balance</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPg0ARW65PH3\" style=\"text-align: right\" title=\"Balance, shares\"> 145,642,333 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 145,642 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7gUKF9UvK4g\" style=\"text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0312\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0303\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 12,920,984 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0305\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 15,497,602 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 680,886 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,111,862 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zK5kX6fWJHQl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Stock transactions</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGVJmOrYkRma\" style=\"text-align: right\" title=\"Stock transactions, shares\">( 1,000,000 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 1,000 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNUlIIAyt4Ja\" style=\"text-align: right\" title=\"Stock transactions, shares\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0324\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0320\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zlVm3Vsq5ZMa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Stock subscription</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXZGSqu0w5dc\" style=\"text-align: right\" title=\"Stock subscription, shares\"> 333,333 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 333 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 333 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0332\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zuNpQ4u1a4j1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued affiliate - 2021 Plan</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgiYARdiYU2c\" style=\"text-align: right\" title=\"Shares issued affiliate - 2021 Plan, shares\"> 1,190,460 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,191 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 130,645 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 131,836 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zg4KbDOdWt8l\" style=\"vertical-align: bottom; background-color: White\"> <td>Shares issued - 2021 Plan</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdko4lo2UAG\" style=\"text-align: right\" title=\"Shares issued - 2021 Plan, shares\"> 1,643,231 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,643 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 166,805 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 168,448 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_ecustom--StockIssuedDuringPeriodValueIssuedForConversionOfAccountsPayableAffiliate_zAG3QtWamkic\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued for the conversion of accounts payable affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_986_ecustom--StockIssuedDuringPeriodSharesIssuedForConversionOfAccountsPayableAffiliate_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuHKreirYhDf\" style=\"text-align: right\" title=\"Shares issued for the conversion of accounts payable affiliate, Shares\"> 3,599,289 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,599 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 482,305 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 485,904 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_ecustom--StockIssuedDuringPeriodValueIssuedForConversionOfAccountsPayable_zQfAwiuGUMx\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Shares issued for the conversion of accounts payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuedForConversionOfAccountsPayableShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIBZ8GHgXXS2\" style=\"text-align: right\" title=\"Shares issued for the conversion of accounts payable, shares\"> 7,409,512 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 7,410 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 877,994 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 885,404 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z39XrikZVOYa\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued for the conversion of notes payable and accrued interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyK3OYbvguQ6\" style=\"text-align: right\" title=\"Shares issued for the conversion of notes payable and accrued interest, shares\"> 9,857,092 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 9,857 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,253,705 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,263,562 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_ecustom--StockIssuedDuringPeriodValueIssuedForConversionOfWarrants_znlovOgylJO\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Shares issued for the conversion of warrants</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuedForConversionOfWarrants_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgT2HLwqth1g\" style=\"text-align: right\" title=\"Shares issued for the conversion of warrants, shares\"> 4,356,778 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,357 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 4,357 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0392\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zvDfG24CcWl2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net loss attributable to the non-controlling interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 13,324 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 13,324 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_405_eus-gaap--NetIncomeLoss_zodsHKS2ISx8\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Net loss</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0404\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0405\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0406\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0407\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 800,329 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"-sec-ix-hidden: xdx2ixbrl0409\">-</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 800,329 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_43C_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zsC3zQniCnjg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">March 31, 2024</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzpSXika68m2\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 173,032,028 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 173,032 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSBo4OGdOAGi\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0422\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0413\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 15,828,748 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0415\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 16,297,931 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 694,210 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 990,361 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_433_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zhoVS1mXiAn1\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">Balance</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6uY8jr3ypPf\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 173,032,028 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 173,032 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDqIZF3Eyco4\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0434\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0425\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 15,828,748 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0427\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 16,297,931 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 694,210 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 990,361 </td><td style=\"text-align: left\">)</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30A_112_zfKTmz9Z6jmk\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_493_20240101__20240331_zR6Dj4Mlhmxb\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20230101__20230331_zyr5RFsZruuf\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">\u00a0</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">3-Months Ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2024</b></span></p></td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2023</b></span></p></td><td>\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zwCAOkx40bHe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--ProfitLoss_i01_maCzHQh_zYeR0mFSqH9e\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 64%; text-align: left\">Net loss</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">( 813,653 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">( 817,977 </td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr id=\"xdx_40A_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zBJCAQDxvHPl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Adjustments to reconcile net loss to net cash used in operating activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--AmortizationOfIntangibleAssets_i02_maCzHQh_zhLN3qMjnoU2\" style=\"vertical-align: bottom; background-color: White\"> <td>Amortization of IP</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,031 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 514 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--ShareBasedCompensation_i02_pp0p0_maCzHQh_zRPF40gpgUP5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Stock-based compensation expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 168,410 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 850 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_ecustom--StockbasedCompensationExpenseAffiliate_i02_pp0p0_maCzHQh_zKPllmrdZJD3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Stock-based compensation expense affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 131,835 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 12750 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--PaidInKindInterest_i02_pp0p0_maCzHQh_zBPmJOWBGfAh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Interest paid for conversion of note</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 163,562 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0455\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zZwGTz7GZ2vj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Changes in operating assets and liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzHQh_zsLegwaBzn7f\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Accounts payable and accrued expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 273,151 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 351,474 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_ecustom--IncreaseDecreaseAccountsPayableAndAccruedExpensesAffiliate_i03_maCzHQh_z24k6Uw3mhCg\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Accounts payable and accrued expenses affiliate</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 903 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 265,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzHQh_maCCERCzF9p_zOFnBKMCoFHd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net cash used in operating activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 75,567 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 186,889 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUzYiy_zeEc3GxumkU7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Investment in intangibles</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 5,995 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 4,711 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzYiy_maCCERCzF9p_zqBqok5SgNd7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net cash used in investing activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 5,995 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 4,711 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--ProceedsFromMinorityShareholders_i01_pp0p0_maNCPBUzZKk_zGctXH5smC2d\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Proceeds from subsidiary stock transactions</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0481\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 50,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--ProceedsFromStockPlans_i01_pp0p0_maNCPBUzZKk_znGdepVinWHd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Proceeds from stock subscriptions</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0485\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUzZKk_z19l9T1EMrqa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Proceeds from issuance of convertible notes payable</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 61,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0488\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzZKk_maCCERCzF9p_zc296NknDch2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net cash provided by financing activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 65,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 50,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCCERCzF9p_z4Aub7ncoXil\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net increase (decrease) in cash</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 16,062 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 141,600 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zaSX5P3uyXI9\" style=\"vertical-align: bottom; background-color: White\"> <td>Cash, beginning of period</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 26,086 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 295,401 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zfgvqguxAq33\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">Cash, end of period</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 10,024 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 153,801 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z7e7ymFgZyri\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--InterestPaidNet_i01_zXsz4QqRUID2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Interest paid</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0505\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 52,425 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zOKTBC9OYjJg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Income taxes paid</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0508\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0509\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zhXrIeTCzxD2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">NON-CASH INVESTING &amp; FINANCING ACTIVITIES</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_ecustom--CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest_i01_pp0p0_ztfUioNSAa5f\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Common shares issued for the conversion of principal and accrued interest</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 1,263,562 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0515\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--StockIssued1_i01_pp0p0_zJl29YMBmeIe\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Common shares issued for the conversion of accounts payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 885,404 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0518\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_ecustom--CommonSharesIssuedForConversionOfAccountsPayable_i01_pp0p0_zCv6dCGuTyn5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Common shares issued for the conversion of accounts payable affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 485,904 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0521\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Estimated Remaining Life (years)</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49F_20240331_zuJ1upYLSzU4\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_495_20231231_zmluYt26ZOOc\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_z0aAiqU0vl11\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 46%; text-align: left\">Capitalized patent costs</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\"><span id=\"xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240331_z2Oakfe2U4Xl\" title=\"Estimated Remaining Life (years)\"> 18 </span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 129,475 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 123,480 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_zJmVvx4IgQ26\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Accumulated amortization</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 13,959 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 11,929 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_z6cslVpNSzzg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Intangible assets, net</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 115,516 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 111,552 </td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20240331_zACnB9HNascc\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2024</b></span></p></td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20231231_zogb8uc404e5\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>December 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2023</b></span></p></td><td>\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AffiliateMember_zEkUk2XD60A5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Accounts payable affiliate <span id=\"xdx_F4E_zDSMqoNe63sc\">(1)</span></td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0699\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 2,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_zIq1va3DCQBb\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Professional fees</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,363 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 70,895 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--InterestPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zB6GQrurysE5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Interest affiliate <span id=\"xdx_F45_zuRlVZ9e3697\">(2)</span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,457 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0706\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--InterestPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zVCwPKgmlPYj\" style=\"vertical-align: bottom; background-color: White\"> <td>Interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 86,571 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 223,759 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zrUZdf6HIiTd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Other</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 657 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,658 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJxuv6yJUjib\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Un-issued share liability, affiliate <span id=\"xdx_F48_zhsCaMuFAsH5\">(3)</span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 515,904 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zby5aQ703F95\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Un-issued share liability, consultant</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,246 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 510,284 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--ShortTermBorrowings_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zaxVEtRNRfLl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Short term loan from Affiliate <span id=\"xdx_F46_z1rE0unFV38h\">(2)</span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 73,107 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--ShortTermBorrowings_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zqDUAU4MdzCe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Short term Loan</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 38,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0724\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_zBIly4TYOt7h\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Convertible note payable</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 861,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,900,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--LiabilitiesCurrent_iI_zRO77mzJWS3i\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 1,115,901 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 3,249,500 </td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span id=\"xdx_F08_zIzADBjl94Ca\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(1)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_F15_zHFgsWfKQlAh\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> On December 31, 2023, there was $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_905_eus-gaap--PrepaidExpenseCurrent_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zwKfRirkfmpg\" title=\"Prepaid expenses\"> 2,000 </span> due to the CFO for advanced expenses. </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span id=\"xdx_F08_z8wrHDPrb781\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(2)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_F14_zRwI4Sla0Xmk\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> On March 31, 2024, the Company has a loan of $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_909_eus-gaap--ShortTermBorrowings_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z30bbF9Nc3u7\" title=\"Short term loans\"> 73,107 </span> from affiliates, the interest is <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90F_eus-gaap--ShortTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zk1AJtlyu9vl\" title=\"Interest rate\"> 8 </span>% and is currently $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90A_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znZu3sHKhM2a\" title=\"Accounts payable\"> 1,457 </span>. On December 31, 2023, the loan was $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90E_eus-gaap--ShortTermBorrowings_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpSvFqNmDSZj\" title=\"Short term loans\"> 25,000 </span>. </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span id=\"xdx_F0F_zoxNV9bljD5h\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(3)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_F16_zURRyWOBR4w8\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> On March 31, 2024, there are <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBy99AwxY9Ti\" title=\"Common stock shares award\"> 241,938 </span> shares of Common Stock awarded but not issued to three Board Members in the first quarter of 2024. The total fair market value at the time of the award was $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_906_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4VLxxc3vxZj\" title=\"Unissued shares liability\"> 30,000 </span>. On December 31, 2023, there were <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1A3tjKjEETf\" title=\"Common stock shares award\"> 211,269 </span> shares awarded but not issued to three Board Members. The total fair market value at the time of the award was $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90C_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zqTMIkiJuXz4\" title=\"Unissued shares liability\"> 30,000 </span>. There were also <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331_zgdn01Zv7uFd\" title=\"Shares not issued but conveted\"> 3,599,289 </span> shares not issued, but converted, from salaries and expenses by the management for a fair market value of $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEVTIEFORCBBQ0NSVUVEIEVYUEVOU0VTIEFORCBPVEhFUiBDVVJSRU5UIExJQUJJTElUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue_c20240101__20240331_z8bojEqGMXF7\" title=\"Fair market value of converted shares\"> 485,904 </span>. </span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Name</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Principal due</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Accrued interest</td><td style=\"font-weight: bold\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Total</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>amount due</b></span></p></td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 42%; text-align: left\">Private Placement, 2021 Note</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 6%; text-align: right\">(1</td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember_fKDEp_z7TpOU9vUxV7\" style=\"width: 12%; text-align: right\" title=\"Total principal due\"> 900,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PrivatePlacementTwoThousandAndTwentyOneNoteMember_fKDEp_zVanEpx0z8Zd\" style=\"width: 12%; text-align: right\" title=\"Total accrued interest\"> 63,814 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_983_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PrivatePlacementTwoThousandAndTwentyOneNoteMember_fKDEp_zm5X9sDuC9D4\" style=\"width: 12%; text-align: right\" title=\"Total amount due\"> 963,814 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2021 Note issued in exchange for prior Notes</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">(2</td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneNoteIssuedInExchangeForPriorNotesMember_fKDIp_zb6cqgUMnE8k\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total principal due\"> 1,000,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneNoteIssuedInExchangeForPriorNotesMember_fKDIp_ztYNstPZAVm9\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total accrued interest\"> 159,945 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyOneNoteIssuedInExchangeForPriorNotesMember_fKDIp_zS1rC0oLwJ48\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total amount due\"> 1,159,945 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_ziMUd6UJ0Yve\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Principal due\"> 1,900,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20231231_zP6rLzGPiCFd\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Accrued interest\"> 223,759 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--ConvertibleNotesPayable_iI_c20231231_z6DAyuyoXn7e\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total amount due\"> 2,123,759 </td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2024</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 42%; text-align: left\">Private Placement, 2021 Note</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 6%; text-align: right\">(3</td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PrivatePlacementTwoThousandAndTwentyOneNoteMember_fKDMp_zEehRQ80rpm1\" style=\"width: 12%; text-align: right\" title=\"Total principal due\"> 800,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PrivatePlacementTwoThousandAndTwentyOneNoteMember_fKDMp_zBPnsDnTV8t4\" style=\"width: 12%; text-align: right\" title=\"Total accrued interest\"> 85,978 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_985_eus-gaap--ConvertibleNotesPayable_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PrivatePlacementTwoThousandAndTwentyOneNoteMember_fKDMp_zvEYhixMvMxf\" style=\"width: 12%; text-align: right\" title=\"Total amount due\"> 885,978 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span id=\"xdx_F0C_ztFxu2tomm0j\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(1)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_F13_z4SKN2ogKknj\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> Net cash received from these notes were $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIENPTlZFUlRJQkxFIE5PVEVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_908_eus-gaap--ProceedsFromConvertibleDebt_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WallachBethCapitalLLCMember_zh4y47hU9Jh8\" title=\"Cash received\"> 1,045,150 </span>, after a Debt Discount of $<span id=\"xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WallachBethCapitalLLCMember_zPaN7puO8Eff\" title=\"Debt discount\"> 119,850 </span> was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC). </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span id=\"xdx_F03_zxEttVslYhSk\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(2)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_F18_zN9fBh8qeyEg\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> All earlier issued Notes were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIENPTlZFUlRJQkxFIE5PVEVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_901_ecustom--DebtInstrumentReissueForSettlementAmount_iI_c20231231_zSeoxN3PkGic\" title=\"New note issued\"> 1,000,000 </span> was issued to a third party. </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span id=\"xdx_F0B_z7Hbzg9SLy4g\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(3)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">In the first quarter of 2024 a total of $<span id=\"xdx_90C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240101__20240331_zQI6RJnMCBgi\" title=\"Shares issued for the conversion of notes payable\"> 1,263,562 </span> (whereof $<span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIENPTlZFUlRJQkxFIE5PVEVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90A_eus-gaap--PaidInKindInterest_c20240101__20240331_zeKgNFCLl2P5\" title=\"Interest paid in conversion of note payable\"> 163,562 </span> in interest) was converted into <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIENPTlZFUlRJQkxFIE5PVEVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTaSoo49wXIc\" title=\"Shares issued for the conversion of notes payable\"> 9,857,092 </span> shares of Common Stock. <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIENPTlZFUlRJQkxFIE5PVEVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA\" id=\"xdx_90C_eus-gaap--DebtConversionDescription_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--FourSecuritiesPurchaseAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneNotesMember_zwdnDOWn3qC3\" title=\"Note conversion description\"> The remaining \u201c2021 Note\u201d has an interest rate of 10% and is convertible at the lower of (i) a fixed price of $0.13, or (ii) if the market price at the date of conversion is below $0.13, the conversion price will be reduced with 120% of the difference between conversion and market price. </span></span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Name</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Principal due</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Accrued interest</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Total</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>amount due</b></span></p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2024</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 46%; text-align: left; padding-bottom: 1.5pt\">Private Placement, 2024 Note</td><td style=\"width: 2%; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td id=\"xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNotesMember_fKDEp_zOn7ECiDeZoj\" style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\" title=\"Principal due\"> 61,500 </td><td style=\"width: 1%; padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td id=\"xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNotesMember_fKDEp_zgn5k7bq6wRk\" style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\" title=\"Accrued interest\"> 593 </td><td style=\"width: 1%; padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--ConvertibleNotesPayable_iI_pid_c20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourNotesMember_fKDEp_zZ0I8NWF1LRl\" style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\" title=\"Total amount due\"> 62,093 </td><td style=\"width: 1%; padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Number of Warrants*</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted Average Exercise Price</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted- Average Remaining Expected Term</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 52%; font-weight: bold\">Outstanding as at January 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230331_fKg_____zDfGYNVYcBok\" style=\"width: 12%; text-align: right\" title=\"Number of Warrants Oustanding, balance\"> 542,030 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230331_z0Jenfd48b05\" style=\"width: 12%; text-align: right\" title=\"Weighted Average Exercise Price, Balance\"> 0.42 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 12%; text-align: right\"><span id=\"xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zzCCzCaIGlp6\" title=\"Weighted- Average Remaining Expected Term, Balance\"> 4.1 </span></td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>Granted</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331_fKg_____z64PsYio0j79\" style=\"text-align: right\" title=\"Number of Warrants, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl0926\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zOQPG1RrQQEg\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl0928\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Exercised</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230331_fKg_____zinvCOMOwN9i\" style=\"text-align: right\" title=\"Number of Warrants, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl0930\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230331_z6GiZneTaXV7\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl0932\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt\">Forfeited/Canceled</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20230101__20230331_fKg_____zxkfLIJQcccj\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Warrants, Forfeited/Canceled\"><span style=\"-sec-ix-hidden: xdx2ixbrl0934\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230331_zzbmTCl8mSQ7\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Weighted Average Exercise Price, Forfeited/Canceled\"><span style=\"-sec-ix-hidden: xdx2ixbrl0936\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">Outstanding as at March 31, 2023</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230331_fKg_____zjMRZ7C0ce08\" style=\"text-align: right\" title=\"Number of Warrants Oustanding, Balance\"> 542,030 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230331_z8oSysXb7oA4\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Balance\"> 1.14 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End_dtY_c20230101__20230331_zHdjd2GKFOcc\" title=\"Weighted- Average Remaining Expected Term, Balance\"> 3.8 </span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">Outstanding as at January 1, 2024</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240331_fKg_____zRK6Qlr92vi9\" style=\"text-align: right\" title=\"Number of Warrants Oustanding, balance\"> 1,342,030 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240331_zVM8lYJo180l\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Balance\"> 0.29 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331_z5Wql8X0s0Fg\" title=\"Weighted- Average Remaining Expected Term, Balance\"> 3.8 </span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>Granted</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240331_fKg_____zIeMv1ZEOVCd\" style=\"text-align: right\" title=\"Number of Warrants, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl0950\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240331_zCkqrp5Gtdvk\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl0952\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Exercised</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240331_fKg_____zain4x6nBAu8\" style=\"text-align: right\" title=\"Number of Warrants, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl0954\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240331_zsn5OebiWao\" style=\"text-align: right\" title=\"Weighted Average Exercise Price, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl0956\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt\">Forfeited/Canceled</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20240101__20240331_fKg_____zK6f7WYVZD2i\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Warrants, Forfeited/Canceled\"><span style=\"-sec-ix-hidden: xdx2ixbrl0958\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240331_zJwHQqxLtoG5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Weighted Average Exercise Price, Forfeited/Canceled\"><span style=\"-sec-ix-hidden: xdx2ixbrl0960\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Outstanding as at March 31, 2024</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240331_fKg_____zJptpPYdGuLg\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Number of Warrants Oustanding, Balance\"> 1,342,030 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331_zPa8VX422eE\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Weighted Average Exercise Price, Balance\"> 0.29 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span id=\"xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End_dtY_c20240101__20240331_znONDC1GGCWi\" title=\"Weighted- Average Remaining Expected Term, Balance\"> 3.5 </span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Warrants Outstanding</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Exercisable Warrants</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Number of Warrants</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted<br/> Average<br/> Exercise<br/> Price<br/> Per Share</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted Average Remaining Contractual Life (Years)</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Aggregate Intrinsic Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Number of Warrants</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted Average Exercise Price Per Share</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Weighted Average Remaining Contractual Life (Years)</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Aggregate Intrinsic<br/> Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlnNpyu9LsMc\" style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\" title=\"Warrants Outstanding, Number of Warrants\"> 1,342,030 </td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td id=\"xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv8eFM4akack\" style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\" title=\"Warrants Outstanding, Weighted Average Exercise Price Per Share\"> 0.29 </td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\"><span id=\"xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJr8TfIFMdmg\" title=\"Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)\"> 3.5 </span></td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td id=\"xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEmybAwiFGa\" style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\" title=\"Warrants Outstanding, Aggregate Intrinsic Value\"><span style=\"-sec-ix-hidden: xdx2ixbrl0987\">\u2014</span></td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z41o7v0P5Sl2\" style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\" title=\"Exercisable Warrants, Number of Warrants\"> 1,342,030 </td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td id=\"xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5HlAWcdxEHg\" style=\"border-bottom: Black 2.5pt double; width: 9%; text-align: right\" title=\"Exercisable Warrants, Weighted Average Exercise Price Per Share\"> 0.29 </td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; width: 8%; text-align: right\"><span id=\"xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znc91dE7c766\" title=\"Exercisable Warrants, Weighted Average Remaining Contractual Life (Years)\"> 3.5 </span></td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"width: 2%; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td id=\"xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iI_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztY0MEog9Z1i\" style=\"border-bottom: Black 2.5pt double; width: 8%; text-align: right\" title=\"Exercisable Warrants, Aggregate Intrinsic Value\"><span style=\"-sec-ix-hidden: xdx2ixbrl0995\">\u2014</span></td><td style=\"width: 1%; padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Number of Shares</b></span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">Fair Value per Share</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">Weighted Average Market Value per Share</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 52%; font-weight: bold; text-align: justify\">Shares Issued as of January 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--SharesIssued_iS_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zSnfeXCqtFib\" style=\"width: 12%; text-align: right\" title=\"Number of Shares, Shares Issued Balance\"> 4,290,709 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90F_eus-gaap--SharesIssuedPricePerShare_iS_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MinimumMember_zYAGZJtCpLok\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.001 </span> \u2013 <span id=\"xdx_902_eus-gaap--SharesIssuedPricePerShare_iS_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zc5vNjcJf1Ej\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.550 </span></span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_987_ecustom--WeightedAverageMarketValuePerShareBeginingBalance_iS_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zhNmH3hDnIc3\" style=\"width: 12%; text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued Balance\">( 0.020 </td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify\">Shares Issued</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zhk7UdgaJ7Li\" style=\"text-align: right\" title=\"Number of Shares, Shares Issued Balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl1033\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_900_ecustom--SharesIssuedPricePerShare1_iI_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zzRig1rdDLOa\" title=\"Fair Value per Share, Shares Issued\"><span style=\"-sec-ix-hidden: xdx2ixbrl1035\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageMarketValuePerShare_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zBoscnGMSmwh\" style=\"text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued\"><span style=\"-sec-ix-hidden: xdx2ixbrl1037\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: justify; padding-bottom: 1.5pt\">Shares Issued as of March 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--SharesIssued_iE_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_z5zsi58x8Ae5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Shares, Shares Issued Balance\"> 4,290,709 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_eus-gaap--SharesIssuedPricePerShare_iE_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MinimumMember_zUCUwC13Vlu3\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.001 </span> \u2013 <span id=\"xdx_902_eus-gaap--SharesIssuedPricePerShare_iE_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zbzxXYyRobJe\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.550 </span></span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_984_ecustom--WeightedAverageMarketValuePerShareEndingBalance_iE_c20230101__20230331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zkJIS8RYAGuh\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued Balance\">( 0.020 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: justify\">Shares Issued as of January 1, 2024</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--SharesIssued_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_znpFtzuO3037\" style=\"text-align: right\" title=\"Number of Shares, Shares Issued Balance\"> 5,288,687 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_905_eus-gaap--SharesIssuedPricePerShare_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MinimumMember_zUFavvxkMyeg\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.001 </span> \u2013 <span id=\"xdx_905_eus-gaap--SharesIssuedPricePerShare_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_z3V6qCtkzF88\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.550 </span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_981_ecustom--WeightedAverageMarketValuePerShareBeginingBalance_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zTPXIeoeYVrl\" style=\"text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued Balance\"> 0.020 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify\">Shares Issued</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zDeocIlb50Cc\" style=\"text-align: right\" title=\"Number of Shares, Shares Issued Balance\"> 2,833,691 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_90C_ecustom--SharesIssuedPricePerShare1_iI_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MinimumMember_zYpg1Vz9wry1\" title=\"Fair Value per Share, Shares Issued\"> 0.106 </span>\u2013 <span id=\"xdx_905_ecustom--SharesIssuedPricePerShare1_iI_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zIKiVbk5VYFg\" title=\"Fair Value per Share, Shares Issued\"> 0.142 </span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageMarketValuePerShare_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zNYVzEorniDb\" style=\"text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued\"> 0.108 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: justify; padding-bottom: 1.5pt\">Shares Issued as of March 31, 2024</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--SharesIssued_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zo6NbOIuznfl\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Shares, Shares Issued Balance\"> 8,122,378 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90B_eus-gaap--SharesIssuedPricePerShare_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MinimumMember_zh89dQMDlRI2\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.001 </span> \u2013 <span id=\"xdx_905_eus-gaap--SharesIssuedPricePerShare_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zL4Qz9HR7gW9\" title=\"Fair Value per Share, Shares Issued Balance\"> 0.550 </span></span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_982_ecustom--WeightedAverageMarketValuePerShareEndingBalance_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--StockAwardsPlanMember_zYIiAoTOtw2j\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Weighted Average Market Value per Share, Shares Issued Balance\"> 0.049 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: justify\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Number of Options</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Exercise</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Price per</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Share</b></span></p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Weighted</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Average</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Exercise</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Price</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>per Share</b></span></p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 52%; font-weight: bold; text-align: justify\">Outstanding as of January 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zfG7LEAyN716\" style=\"width: 12%; text-align: right\" title=\"Number of Options, Outstanding Balance\"> 524,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zsuMUj8WKlQl\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.001 </span> \u2013 <span id=\"xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zUmBs757gyu\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.95 </span></span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\"><span id=\"xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkBK1w6GiX07\" title=\"Weighted Average Exercise Price per Share, Outstanding balance\"> 0.71 </span></td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>Granted</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6OVyFwD7WW9\" style=\"text-align: right\" title=\"Number of Options, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1121\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaKFNbpFZe44\" title=\"Exercise Price per Share, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1123\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK245LFXfzw9\" title=\"Weighted Average Exercise Price per Share, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1125\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: justify\">Exercised</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQncEY8DOlT9\" style=\"text-align: right\" title=\"Number of Options, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1127\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExeercisedExercisePricePerShare_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcHPYJ87ReO6\" title=\"Exercise Price per Share, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1129\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zflrYLl6uE35\" title=\"Weighted Average Exercise Price per Share, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1131\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify; padding-bottom: 1.5pt\">Options forfeited/cancelled</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ3mvL31lRYk\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Options, Options forfeited/cancelled\">( 48,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShareForfeited_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zzkfQJ1AhWJ1\" title=\"Exercise Price per Share, Options forfeited/cancelled\"> 0.15 </span> \u2013 <span id=\"xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShareForfeited_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zsySZGvsK20a\" title=\"Exercise Price per Share, Options forfeited/cancelled\"> 0.32 </span></span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span id=\"xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z877o9wz2ga\" title=\"Weighted Average Exercise Price per Share, Options forfeited/cancelled\"> 0.16 </span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 1.5pt\">Outstanding as of March 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC25zbNS0SDd\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Options, Outstanding Balance\"> 476,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zxtl0GfJkFK6\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.001 </span> - <span id=\"xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zwKFzkBhCPL9\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.95 </span></span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX8wejxZWSi4\" title=\"Weighted Average Exercise Price per Share, Outstanding balance\"> 0.47 </span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: justify\">Outstanding as of January 1, 2024</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxay7bp02cc\" style=\"text-align: right\" title=\"Number of Options, Outstanding Balance\"> 335,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zkMmbvzrdDF5\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.001 </span> - <span id=\"xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zLCs0FGKfZpk\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.95 </span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span id=\"xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9HAl2tWXm69\" title=\"Weighted Average Exercise Price per Share, Outstanding balance\"> 0.62 </span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>Granted</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd1lIyBpshi3\" style=\"text-align: right\" title=\"Number of Options, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1157\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQZln7zAvxXe\" title=\"Exercise Price per Share, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1159\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV6CP4pbRcJj\" title=\"Weighted Average Exercise Price per Share, Granted\"><span style=\"-sec-ix-hidden: xdx2ixbrl1161\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Exercised</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxjPL8bn7CXa\" style=\"text-align: right\" title=\"Number of Options, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1163\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExeercisedExercisePricePerShare_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB2nZt75vQbg\" title=\"Exercise Price per Share, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1165\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaLEeeoUp2N1\" title=\"Weighted Average Exercise Price per Share, Exercised\"><span style=\"-sec-ix-hidden: xdx2ixbrl1167\">\u2014</span></span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Options forfeited/cancelled</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkMxX7p7B6e3\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Options, Options forfeited/cancelled\">( 45,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span id=\"xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShareForfeited_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zH9eQzTKeKK2\" title=\"Exercise Price per Share, Options forfeited/cancelled\"> 0.34 </span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span id=\"xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3bhoawORW31\" title=\"Weighted Average Exercise Price per Share, Options forfeited/cancelled\"> 0.34 </span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 1.5pt\">Outstanding as of March 31, 2024</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQQRjZItReS6\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number of Options, Outstanding Balance\"> 290,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z8EZfWqZal6h\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.001 </span> - <span id=\"xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxfkWBAjJRA2\" title=\"Exercise Price per Share, Outstanding Balance\"> 0.95 </span></span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span id=\"xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK075zUOSzN9\" title=\"Weighted Average Exercise Price per Share, Outstanding balance\"> 0.68 </span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"><td colspan=\"2\" style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Options Outstanding</b></span></td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Exercisable Options</b></span></td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Exercise Price</span></td> <td style=\"font-weight: bold\">\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Number of Options</span></td> <td style=\"font-weight: bold\">\u00a0</td> <td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Weighted Average Exercise Price Per Share</b></span></td> <td>\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Weighted Average Remaining Contractual Life (Years)</span></td> <td style=\"font-weight: bold\">\u00a0</td> <td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Aggregate Intrinsic Value</b></span></td> <td>\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Number of Options</span></td> <td style=\"font-weight: bold\">\u00a0</td> <td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Weighted Average Exercise Price Per Share</b></span></td> <td>\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Weighted Average Remaining Contractual Life (Years)</span></td> <td style=\"font-weight: bold\">\u00a0</td> <td>\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Aggregate Intrinsic Value</b></span></td> <td>\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 1%; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAUkrimuCFs4\" title=\"Exercise Price\"> 0.001 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zCW37mngfpWj\" title=\"Options Outstanding, Number of Options\"> 45,000 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zYqcOWvaICba\" title=\"Options Outstanding, Weighted Average Exercise Price per Share\"> 0.001 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 9%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRygwNIdrB3a\" title=\"Options Outstanding, Weighted Average Remaining Contractual Life (Years)\"> 0.33 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zJO5MZ2U99q9\" title=\"Options Outstanding, Aggregate Intrinsic Value\"> 4,635 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_znsXea2ekgF3\" title=\"Exercisable Options, Number of Options\"> 45,000 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zeEEIbopPXR8\" title=\"Exercisable Options, Weighted Average Exercise Price Per Share\"> 0.001 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 9%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zwdcnsEQJpZ8\" title=\"Exercisable Options, Weighted Average Remaining Contractual Life (Years)\"> 0.33 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"width: 8%; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zx4dTYJxjK6c\" title=\"Exercisable Options, Aggregate Intrinsic value\"> 4,635 </span></span></td> <td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMbxsElBVEEf\" title=\"Exercise Price\"> 0.19 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zqDQd1q8Cmtg\" title=\"Options Outstanding, Number of Options\"> 45,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztrmqWgTufUb\" title=\"Options Outstanding, Weighted Average Exercise Price per Share\"> 0.19 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZalYXJYERBl\" title=\"Options Outstanding, Weighted Average Remaining Contractual Life (Years)\"> 0.08 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zkigyryU5dA3\" title=\"Options Outstanding, Aggregate Intrinsic Value\"><span style=\"-sec-ix-hidden: xdx2ixbrl1211\">\u2014</span></span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zXGtNd1cRtY3\" title=\"Exercisable Options, Number of Options\"> 45,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zzhsM3I54xPf\" title=\"Exercisable Options, Weighted Average Exercise Price Per Share\"> 0.19 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zZawu4jv0Ql5\" title=\"Exercisable Options, Weighted Average Remaining Contractual Life (Years)\"> 0.08 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zji3bPZoT1g2\" title=\"Exercisable Options, Aggregate Intrinsic value\"><span style=\"-sec-ix-hidden: xdx2ixbrl1219\">\u2014</span></span></span></td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxGDUlBq0Nxj\" title=\"Exercise Price\"> 0.95 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z5R8AlzrPiRe\" title=\"Options Outstanding, Number of Options\"> 200,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z3tjnVsi2Nh6\" title=\"Options Outstanding, Weighted Average Exercise Price per Share\"> 0.95 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCUURaF7lZ85\" title=\"Options Outstanding, Weighted Average Remaining Contractual Life (Years)\"> 0.45 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z2YY1Q4jxTB4\" title=\"Options Outstanding, Aggregate Intrinsic Value\"><span style=\"-sec-ix-hidden: xdx2ixbrl1229\">\u2014</span></span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zoiCt3MJjvi2\" title=\"Exercisable Options, Number of Options\"> 200,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDr8KwSLurp3\" title=\"Exercisable Options, Weighted Average Exercise Price Per Share\"> 0.95 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpvW40ZD8Fk\" title=\"Exercisable Options, Weighted Average Remaining Contractual Life (Years)\"> 0.45 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zt9H66LvK8d4\" title=\"Exercisable Options, Aggregate Intrinsic value\"><span style=\"-sec-ix-hidden: xdx2ixbrl1237\">\u2014</span></span></span></td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20240331_zDEZxcab39G2\" title=\"Exercise Price, Lower Range\"> 0.001 </span>-<span id=\"xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20240331_zCMkeFCYReE2\" title=\"Exercise Price, Upper Range\"> 1.21 </span>\u00a0</span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240331_zRyYrD1FwRNf\" title=\"Options Outstanding, Number of Options\"> 290,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20240331_zxI5KCwlOBq8\" title=\"Options Outstanding, Weighted Average Exercise Price per Share\"> 0.68 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331_zRXLcRIJShgl\" title=\"Options Outstanding, Weighted Average Remaining Contractual Life (Years)\"> 0.38 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240331_zX9OGYMTbivk\" title=\"Options Outstanding, Aggregate Intrinsic Value\"> 4,635 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20240331_zrFScrUyaOBh\" title=\"Exercisable Options, Number of Options\"> 290,000 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20240331_ztXdr9ds9jb1\" title=\"Exercisable Options, Weighted Average Exercise Price Per Share\"> 0.68 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331_zo1kopvRyOm5\" title=\"Exercisable Options, Weighted Average Remaining Contractual Life (Years)\"> 0.38 </span></span></td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">$</span></td> <td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240331_zgr5PGDEsrK3\" title=\"Exercisable Options, Aggregate Intrinsic value\"> 4,635 </span></span></td> <td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20240101__20240331_zi6aqUWroSJ5\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>March 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2024</b></span></p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_495_20230101__20231231_zRP3AHot6ifd\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>December 31,</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>2023</b></span></p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--IncomeLossFromSubsidiariesNetOfTax_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zEs8XpbKXxal\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Net loss Subsidiary</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">( 27,191 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">( 333,630 </td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zyoiVRCrOVwe\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Net loss attributable to the non-controlling interest</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 13,324 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 90,258 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_ecustom--NetLossAffectingOwedByCompany_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zVtmtySgmcG2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net loss affecting Bioxytran</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 13,867 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 243,372 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_ecustom--AccumulatedLosses_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zj1DgG3fc6z2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Accumulated losses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,955,108 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,927,917 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40B_ecustom--AccumulatedLossesAttributableToNoncontrollingInterest_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z3k7UjHsyQbi\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Accumulated losses attributable to the non-controlling interest</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 855,160 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 841,836 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_ecustom--AccumulatedLossesAffectingOwedByCompany_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zQYDu6qK4lD7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Accumulated losses affecting Bioxytran</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,099,948 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 3,086,081 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_ecustom--NetEquityNoncontrollingInterest_hsrt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zj5WFjHtZMA2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net equity non-controlling interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 694,210 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 680,886 </td><td style=\"text-align: left\">)</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Compensation of three (3) times the employee\u2019s annual salary upon the Termination Date and any target bonus earned, or if termination occurs within 12 months of a change in control, then the terminated employee shall receive two (2) times the employee\u2019s annual salary and any target bonus earned.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Continued coverage under any health, medical, dental or vision program or policy, in which they were eligible to participate at the time of employment termination, for 12 months.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Provide outplacement services through one or more outside firms of the employee\u2019s choosing up to an aggregate of $<span id=\"xdx_90A_eus-gaap--SupplementalUnemploymentBenefitsSeveranceBenefits_iI_c20240331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zFOsjPZCMxx2\" title=\"Payment of severance upon termination\"> 50,000 </span>.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Research and development</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Process development</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Product development</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 64%\">Regulatory</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">\u2014</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">47,004</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Clinical trials</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">74,000</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Project management</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">27,000</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">18,000</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total research and development</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">27,000</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">139,004</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Payroll and related expenses</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">377,122</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">359,142</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Costs for legal, accounting and other professional services</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">6,676</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">43,113</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Promotional expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">22,000</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">165,251</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Miscellaneous expenses</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">50,749</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">30,132</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total general and administrative expenses</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">456,546</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">597,638</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"text-decoration: underline\">Payroll and related expenses</span> in the three months ended March 31, 2024 were $377,122 compared to $359,142 in the three months ended March 31, 2024. <i>The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.</i></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\">\u00a0</td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">The <span style=\"text-decoration: underline\">Costs for legal, accounting and other professional services</span> in the three months ended March 31, 2024 decreased due to reduced activity for lack of funding.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\">\u00a0</td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"text-decoration: underline\">Promotional expenses</span> in the three months ended March 31, 2024 were $22,000, as compared to $165,251In the three months ended March 31, 2023. Promotional activities were paid upfront without possibility of claw back.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\">\u00a0</td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"text-decoration: underline\">Miscellaneous G&amp;A expenses</span> during the three months ended March 31, 2024 and 2023 was $50,749 and $30,132, respectively. The difference is due to training expenses</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Compensation expense to BoD and Management</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">131,835</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">12,750</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Compensation expense to consultants</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">168,410</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">850</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total compensation expense</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">300,245</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">13,600</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Interest expense</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">26,734</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\">67,221</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Interest expense affiliate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">1,097</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Amortization of IP</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">2,031</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">514</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Total other income (expenses)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">29,862</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">67,735</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Net loss attributable to the non-controlling interest</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">13,324</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">32,894</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net equity non-controlling interest</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">(694,210</td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">(623,552</td><td style=\"text-align: left\">)</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"># of shares</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"># of options</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 39%; text-align: left\">Minority owners cash investment</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 12%; text-align: right\">14,410,000</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 12%; text-align: right\">\u00a0</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\">160,950</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\">160,950</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Bioxytran interest in subsidiary</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">15,000,000</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">1,500</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">1,500</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Total outstanding</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">29,410,000</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">162,450</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">162,450</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 0pt; padding-bottom: 2.5pt; width: 64%; text-align: left\">Net loss attributable to Bioxytran</td><td style=\"padding-bottom: 2.5pt; width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; width: 14%; text-align: right\">(800,329</td><td style=\"padding-bottom: 2.5pt; width: 1%; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt; width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; width: 14%; text-align: right\">(785,083</td><td style=\"padding-bottom: 2.5pt; width: 1%; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 0pt; text-align: left\">Loss per common share, basic and diluted</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">(0.00</td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">(0.01</td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 0pt\">Weighted average number of common shares outstanding, basic</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">162,808,026</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">123,495,291</td><td style=\"padding-left: -10pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Net cash used in operating activities</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">(75,567</td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">(186,889</td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net cash used in investing activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">(5,995</td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">(4,711</td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net cash provided by financing activities</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">65,500</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">50,000</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net increase (decrease) in cash</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">(16,062</td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">(141,600</td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt\">Cash, beginning of period</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">26,086</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">295,401</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Cash, end of period</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">10,024</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">153,801</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"text-decoration: underline\">Net cash used in operating activities</span> was $75,567 and $186,890 in the three months ended March 31, 2024 and 2023, respectively. The decrease was due to a reduction of the research and development activities due to lack of funding.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\">\u00a0</td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">In the Three months ended March 31, 2024 the Company is in the process of filing a patent, and $5,995 was spent in legal fees. in the Three months ended March 31, 2023 the amount was $4,711.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\">\u00a0</td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span style=\"text-decoration: underline\">Cash flows from financing activities</span> were $65,500 and $50,000 in the three months ended March 31, 2024 and 2023, respectively. </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">The <span style=\"text-decoration: underline\">available cash</span> was $10,024 and $153,801 in the end of the Three months ended March 31, 2024 and 2023, respectively.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%\">Cash</td><td style=\"width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\">10,024</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 14%; text-align: right\">26,086</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Total current assets</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">10,024</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">26,086</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td> <td style=\"font-weight: bold\">\u00a0</td> <td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,<br/> 2023</td> <td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Accounts payable and accrued expenses</td> <td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td> <td style=\"width: 14%; text-align: right\">97,591</td> <td style=\"width: 1%; text-align: left\">\u00a0</td> <td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td> <td style=\"width: 14%; text-align: right\">296,312</td> <td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Accounts payable affiliate</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">1,457</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">2,000</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Un-issued shares liability</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">14,246</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">510,284</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Un-issued shares liability affiliate</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">30,000</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">515,904</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Short term loan</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">38,000</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">\u00a0</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Short term loan affiliate</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">73,107</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">25,000</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Convertible notes payable, net of discount</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\">861,500</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: right\">1,900,000</td> <td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Total current liabilities</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">1,115,901</td> <td style=\"text-align: left\">\u00a0</td> <td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td> <td style=\"text-align: right\">3,249,500</td> <td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, <br/> 2024</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,<br/> 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Net working capital</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">(1,105,877</td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">(3,223,414</td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Accumulated deficit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">(16,297,931</td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">(15,497,602</td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Three months ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2024</td><td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31,<br/> 2023</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 64%; text-align: left\">Proceeds from stock transactions</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">4,000</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">50,000</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Proceeds from issuance of convertible notes payable</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">61,500</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Net cash provided by financing activities</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">65,500</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">50,000</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Exhibit No.</b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Title of Document</b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">10.83</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">*</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015358/ex10-83.htm\">Option Agreement for conversion/exchange between Pharmalectin, Inc. and Bioxytran, Inc. shares of Common Stock, dated November 20, 2021.</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">31.1 </span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">*</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015358/ex31-1.htm\">Certification of Principal Executive and Financial Officers pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">32.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">**</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/1445815/000149315224015358/ex32-1.htm\">Certification pursuant to Section 906 of Sarbanes Oxley Act of 2002 (Chief Executive and Financial Officer).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">100 </span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">The following financial statements from the Quarterly Report on Form 10-Q of BIOXYTRAN, Inc. for the quarter ended March 31, 2024 formatted in XBRL: (i) Condensed Balance Sheets (unaudited), (ii) Condensed Statements of Operations (unaudited), (iii) Condensed Statements of Cash Flows (unaudited), and (iv) Notes to Condensed Financial Statements (unaudited), tagged as blocks of text.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.INS</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Instance Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.SCH</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Schema Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.CAL</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.DEF</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.LAB</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.PRE</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">104</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td colspan=\"2\" style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>BIOXYTRAN, INC. </b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td colspan=\"2\" style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Date: April 19, 2024 </span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">By: </span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><i>/s/ David Platt</i></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">David Platt</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Chief Executive Officer</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><i>/s/ Ola Soderquist</i></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Ola Soderquist</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Chief Financial Officer </span></td></tr> </table>"
    ]
}